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ABSTRACT
Soluplus® (SOL), a graft amorphous copolymer, composed of polyethylene glycol, vinyl
acetate and vinylcaprolactam in a ratio of 13: 30: 57, was utilized to prepare solid dispersions
containing felodipine (FEL) or ketoconazole (KTZ) using hot-melt extrusion technology. The
melting point depression approach was utilized to determine the miscibility and solubility of the
model compounds within Soluplus®, of which felodipine demonstrated higher solubility when
compared to ketoconazole (14% vs 4.3% w/w) at room temperature (298K). Moreover, the
solubility parameters of FEL, KTZ and SOL were calculated as 21.76, 26.51 and 21.64,
respectively.
Polarized light microscopy, Fourier transform infrared spectroscopy (FT-IR), Raman
microscopy, differential scanning calorimetry (DSC), X-Ray diffraction (XRD), and scanning
electron microscopy (SEM) were explored to characterize the FEL-SOL solid dispersions, and
FEL was found to be molecularly dispersed in the matrix at a concentration of 10% w/w, which
also demonstrated a higher solubility.
A central composite design (CCD) was applied to optimize the processing parameters for
KTZ-SOL solid dispersions and the final formulation containing 29.8% drug was extruded at a
temperature of 140°C and screw speed of 31 rpm. The robustness of the design was also
examined.
A solid dispersion system of paclitaxel (PTX) was also developed to increase the aqueous
solubility in order to overcome the side effects of its commercial products Taxol ®, which was
accomplished with the addition of a non-ionic surfactant, Cremophor® EL. PolyOxTM WSR N-80
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(Molecular weight: 200,000 Da) was utilized as the matrix carrier, in which the concentration of
PTX was determined as 30%. Various surfactants and solubilizers, including sodium lauryl
sulfate (SLS), Lutrol® F68 (F68) and polyethylene glycol (PEG) 3350 were incorporated into the
formulation. Of these, PEG 3350 was found to increase the solubility of PTX to 9.29 µg/ml (9fold); however, the formulation started to precipitate after 2 hours due to the high energy
amorphous state of PTX. 5% hydroxypropyl methylcellulose acetate succinate (HPMCAS-LF)
successfully postponed the precipitation and maintained the solubility up to 12 hours by forming
hydrogen bonds with PTX. This finding was confirmed by FT-IR analysis.
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CHAPTER 1.
INTRODUCTION
1. 1 Solid dispersion
Currently, many new chemical entities are synthesized by high throughput screening and
computational chemistry which results in good biological activity but poor aqueous solubility.
This ultimately results in poor oral bioavailability and limits further development of final dosage
forms [1, 2]. To address this issue, various techniques have been developed and explored,
including formation of salts[3], polymorphs[4], co-crystal[5], solubilized formulations[6-9],
nanoparticles[10, 11], and more recently, solid dispersion technology which has attracted
increasing interest from both industry and academia[12-18]. Solid dispersions were initially
defined as a solid system in which one or more active pharmaceutical ingredients (APIs) are
dispersed into one inert carrier by Chiou and Riegelman[19]. The carrier could be amorphous or
crystalline, while the API(s) could be either molecularly dispersed into the matrix or dispersed as
aggregates. According to the moleculular arrangement of the API within the matrix and the
physical state of carriers, solid dispersion could be further classified into three categories,
crystalline solid dispersion, amorphous solid dispersion and amorphous solid solution[20-22]
(Figure 1-1). In a crystalline solid dispersion system, multiple phases will exist simultaneously,
which can be identified by differential scanning calorimetry (DSC) with a glass transition
temperature (Tg) corresponding to the carrier and a melting endotherm (Tm) representing the
crystalline drug. Therefore, a solid crystalline dispersion is also referred to as a solid crystalline
suspension[20]. The solubility of a drug substance can be enhanced by the approach of breaking
1

down the size of drug particles into micro or nano region[23]. The amorphous solid dispersion is
generated when the drug is converted into an amorphous state and dispersed throughout the
carrier matrix; however, they have a tendency to revert to their more stable, lower energy
crystalline forms from a thermodynamic standpoint. At the same time, a kinetically induced
recrystallization will also occur since the amorphous solid dispersion often contains a drugconcentrated region [22, 24]. In a solid solution, which can be defined as a particular subgroup of
amorphous solid dispersion, the drug substance is molecularly dispersed into the carrier with
only one single glass transition temperature observed in DSC.

Figure 1-1 State of Solid Dispersion[20]

Basically, there are two types of approaches to produce solid dispersions, fusion-based
method and solvent-based method [22, 24, 25]. A solid dispersion can be prepared by a fusionbased method simply by heating the drug-carrier mixture along with other formulation additives
to a temperature above their glass transition temperature, melting point or eutectic point, and
then followed by cooling at a controlled rate[26-32]. A prerequisite for any material to be
processed by this method is thermal stability [24, 25, 33]. Moreover, the miscibility and
2

compatibility between drug and carrier needs to be seriously considered. The high viscosity of a
molten carrier can lead to phase separation and result in an inhomogeneous dispersion which will
further threaten the stability of the final products[34]. In terms of a solvent-based method, the
hydrophobic drug substances will dissolve with the hydrophilic carriers into their common
solvent which will be evaporated [35-47]. Compared to a fusion-based method, this type of
technology is often operated at a lower temperature which is more suitable for heat sensitive
compounds. However, it is not very straightforward to find a common solvent for the rapidly
increasing NCEs and carriers[22]. Moreover, it is always a hurdle to eliminate the solvent
residue in the solid dispersions. The common methods to produce solid dispersions are listed in
Table 1-1.
Table 1-1: List of methods to produce solid dispersions
Fusion-based methods

Solvent-based methods

Traditional heating and cooling [26, 29, 30]

Traditional evaporation[35-38]

Spray congealing[31]

Spray drying[39, 40]

Hot melt extrusion[28, 32]

Freeze drying[41]

MeltrexTM[48]

Supercritical anti-solvent[43]

Melt agglomeration[27]

Co-precipitation[44]
Electrostatic spinning[45]
Fluid-bed coating[42]
Cryogenic processing techniques[46, 47]
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1. 2 Hot melt extrusion
Hot melt extrusion (HME) is one of most widely applied technologies in the plastic
industry which dates back to the late 1930s, and was introduced to pharmaceutical industry
approximately three decades ago[20, 21, 49-51]. Over the traditional technologies, it offers
several unique and distinctive advantages, for instance, continuous process with limited steps,
solvent free process and ease to scale up. In addition, the HME process has very low deadvolume, which results in less material loss, if the proper screw design, process parameters and
formulation were selected, which is eco-effectively. The applications of HME primarily include
solubility/bioavailability enhancement of poorly water soluble compounds [28, 32], tastemasking[52, 53], controlled/sustained release[54, 55] and solid state stability enhancement[56,
57].
The main drawbacks associated to hot-melt extrusion technology is similar to other
fusion based methods to produce solid dispersions as previously mentioned[14, 20, 22, 24, 25,
33, 49]. Processing at a high temperature may induce thermal degradation of the materials
used[58], which will possibly exclude some of the heat sensitive substances, proteins or peptides,
for instance, to HME applications. Finally, although the number of the suitable polymers for
HME is increasing, it is still not proportional to the needs of the pharmaceutical industry.
1. 2. 1. Equipment and process
For over three decades, extruders have been well developed to meet the demands of
pharmaceutical industry and manufacturing companies have made great effort to design an
extruder that is well adapted to the current good manufacturing practices (cGMPs)[20, 50].
Several fundamental characteristics can be utilized to classify hot melt extruders, for instance,
the number of screws, direction of screw rotation (co-rotating or counter-rotating), degree of
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intermeshing and length of screw barrel (ratio of length/diameter)[21]. A twin screw extruder is
often comprised of the following parts: drive, feed, barrel with screw elements, heating/cooling
device, control panel, torque transducer, assorted dies and downstream processing equipment
(Figure 1-2).

Figure 1-2: Schematic representation of a typical pharmaceutical twin-screw extruder[59]
Generally speaking, a hot melt extrusion process can be defined as process in which the
APIs, carriers and other formulation additives will be mixed and extruded under a high
temperature and shear condition into a specific shape. From the processing prospective, HME
can be theoretically divided into five steps, i) feeding, ii) melting and plasticizing, iii) conveying
and mixing, iv) venting and v) stripping and downstream processing[60, 61]. Each elementary
section may affect the properties of the final extrudates.

5

1. 2. 2. Materials
The materials used in a hot melt extrusion process beyond the APIs can be classified into
three categories, matrix carriers, plasticizers and other formulation additives. All of components
used in HME process are of pharmaceutical grade and thermally stable.
1. 2. 2. 1 Carriers
Carrier materials can be divided into two groups: polymeric and non-polymeric. It is
important to select the proper carrier materials which will affect the formulation and final dosage
forms in many aspects. The commonly used carriers in HME process are listed in Table 1-2.
Table 1-2: List of carrier materials used in HME
Chemical Name
Ammonio methacrylate copolymer[62, 63]
Polyvinyl caprolactam– polyvinyl acetate–
polyethylene glycol graft copolymer[64]
Polyvinyl pyrrolidoneco-vinyl acetate[65,
66]
Hypromellose acetate succinate[66, 67]
Hydroxypropyl cellulose[68]
Poly(vinyl pyrrolidone)[69]
Polyethylene oxide [70]
(Molecular weight>100,000 Da)
Polyethylene glycol[69]
(Molecular weight<100,000 Da)
Hydroxypropyl methylcellulose[54]
Glyceryl palmitostearate [71]
Polyvinyl alcohol–polyethylene glycol
copolymer[72]
Poly(dimethylaminoethylmethacrylatecomethacrylic esters)[66]
Glyceryl trimyristate[71]
Triglyceride tripalmitin[73]
Carnauba wax[74]
Ethyl cellulose[75, 76]
Polyvinyl acetate[77]
Polyvinyl
acetate-polyvinylpyrrolidone
copolymer[78]
Poly(lactide-co-glycolide)[79]

Trade Name
Eudragit® RS/RL
Soluplus®

Tg (°C)
64
70

Kollidon® VA64

101

Aqoat®
KlucelTM
Kollidon®
PolyOxTM

~120
Soften at 130
90-156
-57 to -50

CarbowaxTM
160-210

Eudragit® E

50

PLGA

6

62-67
37-63

Methocel®
Precirol® ATO 5
Kollicoat IR®

Dynasan® 114
Dynasan® 116
--Aqualon®
Sentry® Plus
Kollidon® SR

Tm (°C)

45

52-55
208

55-58
61-65
81-86
130-133
35-40
~35

1. 2. 2. 2 Plasticizers
In order to improve the processing conditions of HME, plasticizers are often incorporated
into the formulation. Theoretically, any low molecule weight substances which can reduce the
secondary bonding between polymer chains and further improve their mobility may be used as
plasticizers. The glass transition temperature and melt viscosity of the polymer can be reduced
due to the enhanced free volume between polymer chains[80]. The selection of suitable
plasticizers for HME is generally on a case-by-case basis, and the study of compatibility with
matrix carrier as well as the plasticization effect should be conducted before the HME process,
which can be easily achieved on DSC. Several substances have already been demonstrated as
plasticizers in extrusion, which include citric acid monohydrate[81], methy paraben[82], low
molecular PEG[83], surfactants[84], triethyl citrate[62, 83], acetyltributyl citrate[83], Vitamin E
succinate[58], and Vitamin E TPGS[58, 85]. In addition to the traditional plasticizers, drugs were
reported to function as plasticizers themselves in many cases [70, 83]. Moreover, supercritical
carbon dioxide (CO2) was recently introduced as a gas plasticizer with some unique benefits.
Beyond the reduction of glass transition temperature of polymer and the operating temperature of
the extrusion process, the incorporation of CO2 can increase the porosity of polymer resulting in
a faster drug release of the dosage forms[76, 86]. It can also be easily removed at the end of the
process without any residue which retains the simplicity of the formulation.
1. 2. 2. 3 Other formulation additives
In order to achieve the desired final dosage forms or prevent the degradation from the
high processing temperature, it is common to incorporate other additives into the formulation,
which include release modifier[87], antioxidants[58], forming agents[76] and swelling
agents[85].
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1. 2. 3 Current commercial products produced by HME
As aforementioned, hot-melt extrusion has demonstrated great versatility in
pharmaceutical applications with its solvent-free and continuous processing, Additionally, HME
readily lends itself to process analytical technology (PAT) and Quality by Design (QbD), which
makes it even more suitable for the pharmaceutical industry. As a result, the contract
manufacturing companies using HME technology are spreading around US and the world [50].
To date, there are already several HME products in the current market (Table 1-3), and many
pharmaceutical companies are making great effort to develop solid dispersion products via HME
technology[20].
Table 1-3: Current commercial products produced via HME[21]
Product

Indication

Company

Lacrisert®

Dry eye syndrome

Merck

ZoladexTM

Prostate cancer

AstraZeneca

Implanon®

Contraceptive

Organon

Gris-PEG

Antifungal

Pedinol Pharmacal Inc.

NuvaRing®

Contraceptive

Merck

Norvir®

HIV

Abbott Laboratories

Kaletra®

HIV

Abbott Laboratories

Eucreas®

Diabetes

Novartis

Zithromax®

Antibiotic

Pfizer

Orzurdex®

Macular edema

Allergan

FenoglideTM

Dyslipidemia

Life Cycle Pharma

Noxafil®

Antifungal

Merck
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1. 3 Material Properties
Certain general pharmaceutical criteria have to be met for all of the materials used in hotmelt extrusion processing, which includes the basic safety and toxicity requirement[49]. In
addition, thermal stability is also a prerequisite for all the components. However, with the
incorporation of suitable plasticizers, proper screw configuration/design and proper selection of
feeding portion, the mean residence time of extrusion process can be shortened, which leaves
open the possibility of processing some thermally sensitive compounds.
1. 3. 1 Properties of APIs
The physico-chemical properties of APIs, including Tg, Tm, phase solubility, hydrogen
bonding, ionic nature, partition coefficient, and polymorphism, etc., have to be carefully
determined during the pre-formulation period before the hot-melt extrusion process, which also
pilot the preliminary screening of carriers[21, 49, 88].
1. 3. 2 Properties of Polymers
The polymers play an important role in the hot-melt extrusion process. It is, therefore,
also necessary to consider the polymer-related properties to select the proper carriers or
determine the suitable processing parameters. Several important parameters of polymers are
listed as below.
1. 3. 2. 1 Glass transition temperature
Glass transition temperature (Tg) is one of most important characteristics of any polymer.
At a temperature above the Tg, there is only short range or asymmetry order in the pattern of
polymer molecules and the chains of polymers have partial flexibility. When the temperature is
below the Tg, the polymer are rigid with poor molecular mobility[89]. At this temperature,
polymers will undergo a glass transition from amorphous (glassy) to crystalline (rubbery) state
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when the polymer liquids are cooled from its melting temperature. Two competitive transitions
might occur during the process. The polymers will turn into amorphous state, if the polymer
monomer has an irregular structure. On the other hand, part of polymers with regular structure
will crystallize. However, from a kinetic standpoint, the process to identify a correct packing
pattern is slow, resulting in a remaining amorphous part of the polymer. Consequently, this type
of polymer is defined as a semi-crystalline polymer and the amorphous part of which will also
undergo a glass transition; however, less pronounced changes in the properties will be observed
for semi-crystalline polymers relative to amorphous polymers[89, 90].
As a matter of fact, the Tg is closely related to hot-melt extrusion process. Normally, the
processing temperature of hot melt extrusion is set up as 15-60°C above the melting point of
semi-crystalline polymers or the Tg of amorphous polymers to reduce the torque required to
rotate the screws[91, 92]. From a processing prospective , a polymer with low glass transition
temperature, for instance, Soluplus® (approximately Tg =70°C[93]), will be beneficial, since
extrusion of polymers with higher Tg often requires a higher processing temperature might lead
to degradation of either the polymer or the APIs.
1. 3. 2. 2 Viscosity
Theoretically, viscosity represents the resistance of a fluid to the flow. Unlike the liquid
materials, whose viscosity is an intrinsic property, only affected by temperature and pressure, the
viscosity of a polymer melt inside the hot-melt extruder is more complicated since the polymer
melt is viscoelastic, resulting in a combination of viscosity and elastic effect on its flow[94]. The
viscosity of the polymer melts will depend on the polymer properties as well as the processing
conditions. The following equation can express the viscosity of a pseudoplastic fluid which most
of polymer will behave as during the hot-melt extrusion process[60].

10

η= K ×γ𝑛−1 .......................................................................................................Equation 1-1
Whereas, η is the viscosity of the polymer melt, γ is the shear rate, K is an exponential
function of the temperature and related to the properties of the polymer, and n is the power law
constant (typically 0.25 ≤n ≤0.9 for polymer melts).
The viscosity of the polymer at a fixed shear rate can be expressed as the following
Arrhenius equation[51]:
η=K' ×eEa/RT ………………………..................................................................Equation 1-2
Whereas, η is the viscosity of polymer melts, K’ is a constant depending on the structure
and molecular mass of the polymer, Ea is the activation energy of the polymer for the flow
process and is constant for the same type of polymer, R is the gas constant and T is the
temperature in Kelvin degree.
1. 3. 2. 3 Hygroscopicity
As previously mentioned, water can function as a plasticizer itself and tremendously
affect the physical stability of amorphous solid dispersions. This is particularly true during
storage, therefore, the hygroscopicity of polymer needs to be paid close attention to when
selecting suitable carriers. It has been reported that water can threaten the physical stability of
solid dispersions through numerous pathways, for instances, weakening the drug-polymer
intermolecular interactions, decreasing the solubility/miscibility of the drug within polymers
resulting in phase separation, or reducing the glass transition temperature leading to enhanced
molecular mobility. In terms of stabilization of amorphous solid dispersions, hydrophobic
polymers with ionic groups in the structure, for instance, HPMC-AS or Eudragit® L/E 100, have
been demonstrated a better capacity[95].
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1. 3. 2. 4 Solubility parameter
Solubility parameter δ is one of the approaches to quantify the cohesive energy, which
represents the strength of attraction between constituent molecules in the substance. In other
words, it determines the energy input required to remove one molecule from its adjacent
molecule to an infinite distance, from a thermodynamic standpoint [88, 94, 96]. All kinds of
intermolecular interactions, including Van der Waals, covalent bonding, hydrogen bonding, ionic
and electrostatic interactions, will contribute to the cohesive energy[96]. It has been broadly
applied to estimate the likelihood of drug-polymer miscibility since it was first introduced by
Hildebrand[69, 70, 97-100]. The solubility parameter was initially defined as[100]:
𝐸

𝛿 = ( 𝑉𝑇 )1/2……………………………………………………………………Equation 1-3
Where, ET is the cohesive energy and V is the molar volume.
It was pointed out by Hansen that not only the contribution from dispersion forces Ed, but
also from the polar forces Ep and the hydrogen bonding Eh should be accounted when predicting
the cohesive energy of substances[101]. Hence, the overall cohesive energy can be written as:
𝐸𝑇= 𝐸𝑑 + 𝐸𝑝 + 𝐸ℎ ……………………………………………………………..Equation 1-4
The solubility parameter can be further expressed as:
δ2𝑇 = δ2𝑑 + δ2𝑝 + δ2ℎ . ………………………………………………………….Equation 1-5
Two group contribution methods, the Hoy method and Hoftyzer/Van Krevelen method,
were developed to determine the solubility parameter based on the Hansen’s assumption[94,
102].
In Hoy method, for small molecular weight substances:
𝛿𝑇 = (𝐹𝑖 + 𝐵)/V…………………. …………………………………………..Equation 1-6
For amorphous polymers:
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𝛿𝑇 = (𝐹𝑖 + 𝐵/𝑁)/V………………………………………………………….. Equation 1-7
Where Fi is the summary of molar attraction of each component in the structure; B, as a
constant, is the base value, N is the number of repeating units in each effective chain and can be
calculated as:
(𝑃)

𝑁 = 0.5/𝛥𝑇 ……………. ………………………………………………….Equation 1-8
Where the ΔT is the Lydersen correction for non-ideality.
In Hoftyzer/ Van Krevelen method:
𝛿𝑑 =

∑ 𝐹𝑑𝑖
𝑉

, 𝛿𝑝 =

2
√∑ 𝐹𝑝𝑖

𝑉

∑ 𝐸ℎ𝑖

, 𝛿ℎ = √

𝑉

………………………………………… Equation 1-9

Where, Fdi, Fpi, and Ehi are the different component group contributions in the chemical
structure[94].
1.4 Thermodynamic aspects and melting point depression
As mentioned before, APIs will be mixed with carriers and other formulation ingredients
in hot-melt extrusion processing. For the mixing of two or more components at a constant
temperature and pressure, the change of free energy of mixing could be expressed as the
followed equation:
ΔG=ΔH-TΔS………………………………………………………………...Equation 1-10
Where ΔG is the Gibbs free energy of mixing, ΔH is the enthalpy of mixing, ΔS is the
entropy of mixing and T is the temperature at which the mixing occurs.
The entropy of mixing represents the combination of arrangements of molecules in the
lattice according to the Flory-Huggins theory which is a statistical treatment of the polymer
solution. For blends of small molecular weight substances, the combinatorial entropy, which
represents the number of arrangements of each component in the lattice, mainly determines
whether they are miscible, immiscible or partially miscible; however, with increasing molecular
13

weight, the substance would occupy more positions in the lattice resulting in a decrease of
combinatorial entropy. Therefore, other than combinatorial entropy, factors like the noncombinatorial entropy and the enthalpy of mixing would dominate the miscibility of the
mixture[103].
The phenomenon of melting point depression was broadly observed in the field of
polymer blends [104-107], and was further introduced into study the miscibility/compatibility of
drug-polymer systems based on the assumption that the drug-polymer system is analogous to the
solute-solvent system in the Flory-Huggins theory which is a lattice based, statistical model[108]
[109-112]. It is illustrated that the chemical potential of the drug would diminish during the
melting process if the drug was miscible with polymer and could dissolve in it which would lead
to the drop-off of melting point. The drug-polymer interaction parameter χdrug-polymer could be
calculated by Equation 4:
1
𝑇𝑚

1

− 𝑇 0 = − ∆𝐻

𝑅

𝑓𝑢𝑠𝑖𝑜𝑛

𝑚

1

[𝑙𝑛∅𝑑𝑟𝑢𝑔 + (1 − 𝑚) ∗ (1 − ∅𝑑𝑟𝑢𝑔 ) +

𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟 (1 − ∅𝑑𝑟𝑢𝑔 )2]………………………………………………………. Equation 1-11
Where Tm and Tm0 are the melting point of drug in the binary mixture and pure crystalline
drug, respectively, R is the gas constant, ΔHfusion is the heat of fusion of the pure drug, ϕ is the
volume fraction of drug, and m is volume ratio of polymer to the lattice and can be estimated as:
𝑚=

𝑀𝑊 (𝑝𝑜𝑙𝑦𝑚𝑒𝑟)/𝜌(𝑝𝑜𝑙𝑦𝑚𝑒𝑟)
𝑀𝑤 (𝑑𝑟𝑢𝑔)/𝜌(𝑑𝑟𝑢𝑔)

……………………………………………….. Equation 1-12

At the same time, χdrug-polymer is variable with temperature and can be mathematically
expressed as[103]:
𝐵

𝜒 (𝑇) ≅ 𝐴 + 𝑇 ……………………………………………………………… Equation 1-13
Where both of A and B are constants.
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Another approach to estimate the interaction parameter is by using the solubility
parameter which was development by Hildebrand and Scott[100]:
𝜒=

𝜈(𝛿𝑑𝑟𝑢𝑔 −𝛿𝑝𝑜𝑙𝑦𝑚𝑒𝑟 )
𝑅𝑇

2

……………… ………………………………………Equation 1-14

Where ν is the volume per lattice site, δ is the solubility parameter, R is the gas constant
and T is the temperature. The Hildebrand method only considers the dispersion force and was
suitable for the nonpolar mixtures. Further modification of this method was conducted with the
involvement of the polar forces and hydrogen bonding, resulting in a more precise prediction.
However, in the current study, to simplify, the authors only took the established values from
peers as the solubility parameter and hence the calculated χ value was used only as a reference.
For more details about the group additive methods, the readers are encouraged to reference the
valuable textbook[94].
A complete phase diagram of the drug-polymer binary system could be generated
according to the highly temperature dependent Gibbs free energy of mixing:
Δ𝐺𝑚𝑖𝑥 = 𝑅𝑇[∅𝑑𝑟𝑢𝑔 𝑙𝑛∅𝑑𝑟𝑢𝑔 +

1−∅𝑑𝑟𝑢𝑔
𝑚

ln(1 − ∅𝑑𝑟𝑢𝑔 ) +

𝜒𝑑𝑟𝑢𝑔−𝑝𝑜𝑙𝑦𝑚𝑒𝑟 ∅𝑑𝑟𝑢𝑔 (1 − ∅𝑑𝑟𝑢𝑔 )………………………………………………….. Equation 1-15
Therefore, the binodal curve (Tb-∅drug), which represents the coexistence of two
components in one phase without phase separation, could be extrapolated by the common
tangent method.
𝜕∆𝐺

𝜕∆𝐺

( 𝜕∅ )∅=∅1 = ( 𝜕∅ )∅=∅2 ……………………………………………………...Equation 1-16
The above equation (9) can be solved by numerical analysis using Matlab or other
computational softwares. It is worth pointing out that for any composition between ∅1 and ∅2
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(the difference is called as miscibility gap), the binary system can be spontaneously stabilized by
separation into ∅1 and ∅2.
The following spinodal curve (Ts--∅drug), which is the boundary of metastable and
unstable region, could be plotted by equalizing the second derivation of ΔGmix to zero, hence:
Ts =

2B
1

……………………………………………………. Equation 1-17

1
+
−2A
∅drug m(1−∅
drug )

1. 5 Supersaturating drug delivery system
According to the Fick’s first law, the drug absorption depends on the permeability
coefficient and concentration in the gastrointestinal tract (GIT)[113]. Therefore, to achieve good
solubility is a crucial factor for achieving acceptable bioavailability of biopharmaceutical
classification system’s (BCS) class II or IV drugs. Solid dispersions can enhance the solubility of
poorly water soluble compounds through converting the drug from its crystalline form to its
amorphous form, which is a relatively higher energy state. As a result, the concentration of drug
in solution may be higher than its saturated concentration when the formulation is entering the
gastrointestinal tract and a supersaturated solution is obtained. However, the amorphous state is
usually thermodynamically unstable, and it has the tendency to lower the energy through a
precipitation pathway during dissolution, which will possibly limit the absorption [114, 115].
More time for drug absorption will be provided if the precipitation step is delayed or prohibited.
Various pharmaceutical excipients, including polymers[116-119], surfactants[120, 121]and
cyclodextrins [122, 123], have been applied for this purpose.
1. 6 Design of Experiment (DoE)
Design of experiments (DOE) has been recently introduced to pharmaceutical
development and recommended by the US Food and Drug Administration (FDA) from a quality
by design (QbD) prospective, which was thoroughly discussed in ICH guidelines Q8, Q9 and
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Q10. In addition to process analytical technologies (PAT), multivariate data-analysis and/or prior
knowledge, a robust process or product with good qualities can be achieved. Response surface
methodology (RSM) is an approach comprised of mathematical and statistical techniques for the
development, improvement and optimization of processing or product development which can
model the responses of dependent variables from the alteration of the independent variables by
using a sequence well-designed experiments[124]. It has been utilized in many aspects of
industry and is now applied in pharmaceutical product development.
1. 7 Materials
1. 7. 1 Polymeric carriers
Soluplus®
Soluplus® (SOL), kindly gifted from BASF SE (Ludwigshafen, Germany), is a graft
amorphous copolymer of polyethylene glycol, vinyl acetate and vinylcaprolactam at a ratio of
13: 30: 57. The low glass transition temperature and good flowability make Soluplus® suitable
for hot melt extrusion process. In addition, due to its amphiphilic structure, it can be used as a
surfactant to improve the solubility of poorly water soluble compounds. Moreover, it is soluble
in many solvents which also provides the possibility to be used in spray drying technique. The
chemical structure and properties of Soluplus® are listed as below (Figure 1-3).
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Figure 1-3: Chemical structure of Soluplus®
Table 1-4: Properties of Soluplus®[93]
Properties

Determination Method

Value

Average Molecular Weight

Gel Permeation

118, 000 g/mol

Chromatography
Particle Size

Laser Diffraction

340 µm

Tg

DSC

70°C

Critical Micelles Concentration (CMC)
Solubility Parameter

7.6 mg/L
Gas Chromatography

19.4 MP1/2

PolyOxTM WSR N-80
Polyethylene oxide (PolyOxTM, PEO) is a semi-crystalline, non-ionic, hydrophilic
polymer with a low melting point temperature, ranged from 57 to 73°C, which is suitable for the
hot melt extrusion process. In addition, based on the molecular weight, it has different
gelling/swelling properties and has been utilized to regulate the drug release from the matrix. It is
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believed that the larger the molecular weight is, the longer diffusion pathway the drug will
undergo, which will result in a sustained release[125]. Therefore, PolyOxTM WSR N-80 (MW:
200,000 Da), kindly supplied by Dow Chemical Company (Midland, MI, USA), is expected to
enhance the solubility of poorly water soluble compounds while maintaining the solubility due to
its gelling property.
1. 7. 2 Model drugs
Felodipine (FEL), a long-acting 1,4-dihydropyridine-calcium channel blocker used for
hypertension[126], with a poor aqueous solubility, was purchased from Ria International LLC
(East Hanover, NJ). Ketoconazole (KTZ), for the treatment of the systemic fungal
infections[127], was supplied by Afine Chemicals Ltd. (Hangzhou, Zhejiang, China).

Figure 1-4: a. Structure of Felodipine; b. Structure of Ketoconazole
Currently, cancer has become one of the greatest threats to people’s health, and hence
anti-cancer agents are a focus of research by many investigators. Paclitaxel (PTX, Figure 1-5) is
one of the most useful anticancer agents, originally derived from the bark of the western yew
tree, Taxus brevifolia, with an extremely low aqueous solubility, reported as less than 1
µg/ml[128, 129]. It has been used for various cancers, including ovarian, breast, lung, and brain
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and neck cancers[130]. The current marketed product of paclitaxel is Taxol®, using a mixture of
Cremophor® EL and ethanol as a vehicle for the delivery of paclitaxel. However, this product has
been reported to have serious adverse effects, for example, neutropenia and peripheral
neuropathy, which limits the use of paclitaxel for cancer chemotherapy [131, 132]. These sideeffects have been mainly attributed to Cremophor® EL[133], which is a non-ionic solubilizer and
surfactant, produced by reaction between ethylene oxide and castor oil of German
Pharmacopoeia (DAB 8) quality in a molar ration of 35:1[134], although, paclitaxel has some
side-effects itself. Thus, new drug delivery systems for paclitaxel without Cremophor® EL are
needed and great efforts have been made, however, very few formulations were prepared using
solid dispersion technique[129, 135, 136].

Figure 1-5: Structure of PTX (5β, 20-Epoxy-1, 2α, 4, 7β, 13α-hexahydroxytax-11-en-9-one4, 10diacetate2-benzoate13-ester with (2R, 3S)-N-benzoyl-3-phenyllisoserine)
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1. 7. 3 Other excipients, chemicals and reagents
Hydroxypropyl methylcellulose E5 (Methocel™, HPMC E5) was supplied by Colorcon,
Inc (West Point, PA, USA), hydroxypropylmethylcellulose acetate succinate (HPMCAS HF and
LF grades) was supplied by Shin-Etsu Chemical Co., Ltd (Tokyo, Japan), polyvinylpyrrolidone
(Kollidon® 17PF) and Pluronic® F68 were provided by BASF SE (Ludwigshafen, Germany),
polyethylene glycol 3350 (PEG 3350), sodium hydroxide, monobasic potassium phosphate and
tribasic sodium phosphate were purchased from Sigma-Aldrich LLC. (St. Louis, MO, USA).
Sodium lauryl sulfate (SLS) was purchased from Fisher Scientific (Fair Lawn, NJ, USA). All the
organic solvents and water used in the study were high performance liquid chromatography
(HPLC) grade.
1.8 Objectives
 To investigate the phase diagram of drug-polymer solid dispersion
 To investigate Soluplus® as a polymeric carrier for solubility enhancement of poorly
water-soluble compound
 To investigate the influence of formulation factor and processing parameter on solid
dispersions produced via HME
 To develop a solid dispersion formulation of paclitaxel with enhanced solubility
 To investigate the precipitation inhibition effect of different excipients
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CHAPTER 2
INVESTIGATE THE PHASE DIAGRAM OF DRUG-POLYMER SOLID DISPERSIONS
2. 1 Methods
2. 1. 1 Physical mixtures preparation
The FEL-SOL or KTZ-SOL physical mixtures were prepared using drug concentration of
100, 95, 90, 85, 80, 70, 60, 50 and 40% (w/w). The two components were geometrically mixed
and triturated using a mortar and pestle. All of the materials were sieved with USP 60 mesh prior
to mixing. The physical mixtures were then stored in a vacuum desiccator with silica at room
temperature until further use.
2. 1. 2 Preparation of solid dispersions
Physical mixtures were prepared in 50 g batches containing 10, 30, 50, 60, and 70% drug
loadings, and were initially sieved and mixed in a V-cone blender (MaxiBlendTM,
GlobePharma,North Brunswick, NJ, USA) at 50 rpm for 15 min. The physical mixtures were
then extruded with a co-rotating twin-screw extruder (16 mmPrism EuroLab, ThermoFisher
Scientific, Stone, UK) into uniform rods at an extrusion temperature of 140°C and a screw speed
of 100 rpm. The extrudates were milled into fine powders using a laboratory grinder and further
sieved with USP Mesh No. 60.
2. 1. 3 Differential scanning calorimetry (DSC)
DSC studies were conducted on the physical mixtures using a differential scanning
calorimeter (Diamond DSC, PerkinElmer) equipped with Pyris software (Shelton, CT, USA).
Approximately 5-7 mg of the physical mixture samples were packed into a hermetically sealed
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aluminum pan. Upon analysis, the samples were initially heated from 30-120°C at a rate of
10°C/min and further heated to 170°C at a rate of 1°C/min, respectively. Extrudates were heated
from 30-170°C at a rate of 10°C/min during the overall heating cycle to detect the glass
transition temperature. The glass transition temperature of the individual components was
determined by heating from 30-170°C at a rate of 10°C/min, cooling down to 30°C at a rate of
40°C/min, and reheating to 170°C at a rate 10°C/min. The instrument was calibrated with indium
and zinc before testing. Nitrogen was used as purge gas at a flow rate of 20 mL/min. All the
experiments were performed in triplicate.
2. 1. 4 Theoretical prediction of glass transition temperature (Tg).
The Tgs of the solid dispersions were theoretically predicted according to three equations,
1), Fox equation[137]:
1
𝑇𝑔𝑚𝑖𝑥

=

𝑤1
𝑇𝑔1

+

𝑤2
𝑇𝑔2

……………………………………………………………Equation 2-1

2), Gordon-Taylor equation[138] and 3), Couchman-Karasu equation[139]:
𝑇𝑔𝑚𝑖𝑥 =

𝑤1∗ 𝑇𝑔1 +𝑘∗𝑤2 ∗𝑇𝑔2
𝑤1 +𝑘∗𝑤2

𝑇𝑔 ∗𝜌

∆𝐶𝑝

, 𝑤ℎ𝑒𝑟𝑒, 𝑘𝐺−𝑇 = 𝑇𝑔1 ∗𝜌1 , 𝑘𝐶−𝐾 = ∆𝐶𝑝1 ……………Equation 2-2
2

2

2

Where the Tg mix is the theoretical Tg of the binary system, Tg1, 2 were the Tgs of each
individual component, and the w1, 2 were the weight fraction of each component, ρ1, 2 were the
true density of each component which were measured in Micromeritics AccuPyc 1330
Pycnometer, ΔCp1, 2 was the heat capacity of each of the components, and the KG-T and KC-K
were the constant for the Gordon-Taylor and Couchman-Karasu equation, respectively.
2. 2 Results& Discussion
2. 2. 1 Melting Point Depression
Generally, a melting point depression is often observed when the substance is melting
with impurities. For a pure crystalline drug at the melting point temperature, the chemical
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potential of both the solid state and molten state is equals[140], and for the drug polymer
mixtures, the melting point temperature of the drug could be reduced if the drug can dissolve in
the polymer due to the thermodynamics of mixing. A large depression would be expected if the
mixing is strongly exothermic, while weekly exothermic, athermal or endothermic mixing would
lead to noticeably decreased reductions of the melting point[110]. Recently, many
pharmaceutical scientists were trying to determine a rational choice of heating rate when
investigating the drug-polymer solid dispersion systems: however, no consensus has been
reached, and the debate is still continuing. The heating rate varies from 0.1 to 400°C/min [109112, 141, 142]. A slow scan rate is assumed to provide sufficient time to achieve molecular level
mixing [141], hence, the heating rate used was 1°C/min in the current study. Another issue
regarding the melting point depression measurement is whether to use the onset, midpoint or
offset values to predict the interaction parameter. A thorough discussion was conducted by
Marsac and co-researchers[110]. The offset values were recommended to be applied when
studying the melting point depression since they represent the complete melting of the
systems[104]. However, it still requires more effort to understand the details. In the current
study, both the onset and offset values were compared. Both systems demonstrated a similar
degree of melting point depression (~5°C) when utilizing the offset values. Interestingly, a
discrepancy between the two systems was observed when the onset values were applied. With an
increase of Soluplus® concentration, the onset of endothermic peak of felodipine was obviously
depressed, which illustrated the felodipine is at least partially miscible with Soluplus® (Fig 2-1a).
Instead, the melting peaks corresponding to ketoconazole were slightly shifted towards the lower
temperature, which is an evidence of immiscibility of the binary mixture (Fig 2-1b).
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Figure 2-1a: Melting point depression of FEL-SOL physical mixtures

Figure 2-1b: Melting point depression of KTZ-SOL physical mixtures
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It is clearly shown in Fig 2-2a and 2-2b that the onset melting temperature of both
felodipine and ketoconazole decreased with an increase in the concentration of Soluplus®.
However, a much larger reduction of the melting point from the FEL-SOL systems was observed
compared to the KTZ-SOL system, which indicated that felodipine was possibly more miscible
with Soluplus® than ketoconazole was. This phenomenon was similar with the study reported by
Marsac et. al. that felodipine demonstrated a larger melting point depression than ketoconazole
when mixing with polyvinylpyrrolidone K12[110]. Our observation is that the onset value of the
melting point is referred to the start point of the melting event, and there would be more
Soluplus® molecules surrounding the felodipine molecules due to the smaller molecular
weight/size compared to the ketoconazole molecules which would further lead to a larger
depression of the onset values.
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Figure 2-2a: Plot of melting temperature vs concentration of FEL-SOL system
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Figure 2-2b: Plot of melting temperature vs concentration of KTZ-SOL system
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2. 2. 2 Interaction parameter χ
The interaction parameter χ values for the FEL-SOL and KTZ-SOL systems were
calculated as 3.57/15.48 and 12.21/20.03 according to the F-H equation, (onset/offset,
respectively) which indicates the system is not favorable for mixing at the room temperature and
a strong repulsive force exists between the drug and polymer molecules, however, the calculated
χ values are consistent with the assumption that felodipine would be more miscible with
Soluplus® compared with ketoconazole. Meanwhile, the solubility parameter was also used to
estimate the miscibility of drug-polymer systems as it is broadly accepted that the binary system
is miscible if the difference of solubility parameter is less than 7 MP1/2, and immiscible while the
difference is larger than 10 MP1/2[98]. To simplify, the solubility parameter of Soluplus® was
taken as 19.4 according to technical information from BASF[93], the solubility parameter of
felodipine is 25.0 referred the previous work from Marsac[109], and the solubility parameter of
ketoconazole is calculated as 19.45[97] (Table 2-1).
Table 2-1: Properties of Soluplus®, Felodipine and Ketoconazole
Soluplus®

Felodipine

Ketoconazole

118000

384.26

531.43

68

42.95

44.92

ΔHfusion (KJ/mol)

______

30.83

56.65

δ (MP1/2)

19.4[93]

25.0[109]

19.45[97]

ν (cm3/mol)

98819.19

271.04

372.89

ρ (g/cm3)

1.1941

1.4177

1.4332

ΔCp (J/(g*°C))

0.155

0.376

0.44

MW (g/mol)
Tg (°C)
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The differences indicated that both of the drug-polymer systems are likely to be miscible,
however, this was in contradiction with the prediction from the Flory-Huggins theory. The
interaction parameter χ of FEL-SOL and KTZ-SOL systems were further calculated as 3.429 and
0.00037, respectively. Although both of the positive χ values also indicated the possible partial
miscibility, if not immiscibility, of the two binary systems, it was interesting to find out the
significant difference between the χ values of ketoconazole calculated from two methods while
the χ values of felodipine were close to each other. This result was might be due to the various
algorithmic strategies employed when calculating the solubility parameter[101, 143], since the
parameters used here were taken from different sources. Another possibility is due to the limits
of lattice-based theory which does not account for the free volume change during the mixing
process or the intermolecular interactions [90, 103, 140]. Moreover, the depression of the
melting point is not only related to the thermodynamic effect of mixing, but also associated with
other factors, for instance, the morphology of the polymer. It has been reported that the
crystalline lamellar thickness affected the depression and the authors suggested using the
equilibrium melting temperature instead of the apparent melting point[144]. Lastly, since the
melting point temperature of KTZ-SOL system only slightly altered in a large weight fraction
range from 50-95%, the solid-liquid boundary could be above the melting point of ketoconazole,
and in that case, the assumption of the Flory-Huggins theory would not exist. However, since the
solubility parameters were only used here as a reference, the further discussion would not be
conducted and the interaction parameter χ values calculated from the melting point depression
were used to construct the overall phase diagrams for both systems.
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2. 2. 3 Construction of the F-H phase diagram
Figure 2-3a and 2-3b shows the linear fit of χ value (obtained from offset values) versus
1/Tm at different compositions, a good linearity was achieved for both of the two systems. In
equation 1-13, the constant A is representing the non-combinatorial entropic part, while B/T is
the contribution from the enthalpy of mixing[103]. Janssens[22] and Qian[145] recently
illustrated that χ is a function of temperature instead of a constant as it was proposed in the Flory
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theory. Hence, a series of χ values at different temperature could be obtained.
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Figure 2-3:Plot of χ vs 1/Tm of FEL-SOL system (a), Plot of χ vs 1/Tm of KTZ-SOL system (b)
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The Gibbs free energy of mixing-drug composition diagrams of felodipine and
ketoconazole were further generated by fitting the χ values into equation 1-15, and were shown
as Figure 2-4a and Figure 2-4b, respectively.

a

b

Figure 2-4: Free energy of mixing vs concentration of FEL-SOL system (a), Free energy of
mixing vs concentration of KTZ-SOL system (b)
A negative ΔG value indicates that the mixing is thermodynamically favored and
miscibility could be achieved, while a positive value indicates a likely partial miscible or
immiscible system. The different miscibility of felodipine and ketoconazole in Soluplus ® was
observed since FEL-SOL system demonstrated a less ΔG value. According to the traditional
thermodynamics theories, the Gibbs free energy of mixing is dependent on the temperature;
therefore, a phase diagram could be generated to offer an overall understanding of the solid
dispersion under the treatment of temperature. A typical phase diagram consists of two
curves[90, 103]; one is the binodal curve, which represents the phase boundary between single
phase and two phases, in which the drug-rich domain and polymer-rich domain could coexist and
the binary system is a metastable state; another curve is called as spinodal, which discriminates
the unstable and metastable regions. For any points between the binodal and spinodal curves, the
systems can stand for a small fluctuation and phase separation happens only if the fluctuation is
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large enough to create a nuclei with a critical size. On the other hand, phase separation would be
expected to occur spontaneously if the drug composition in the solid dispersion located below the
spinodal curve[103, 146]. It is important to point out that for any binary mixtures, the binodal
and spinodal curve will always meet at one critical point. It is very valuable to be able to
construct the phase diagram when formulating solid dispersions for poorly water-soluble
compounds, since it frequently promotes the compounds to a high energy, metastable state, for
instance, converting the compounds from crystalline to amorphous, and a recrystallization during
the storage is associated most often. The points between binodal and spinodal curves provides
information to the formulation scientists about the achievable drug loading, processing and
storage temperature [109, 111, 112]. The phase diagrams of FEL-SOL and KTZ-SOL systems
were shown as Figure 2-5a and 2-5b, respectively.

b

a

Figure 2-5: Phase diagram of FEL-SOL system (a), Phase diagram of KTZ-SOL system (b)
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At the temperature of 298K, the FEL-SOL solid dispersions could contain approximately
14% (w/w) drug in the metastable state while the KTZ-SOL solid dispersions could only contain
approximately 4.3% (w/w). However, the solubility of felodipine and ketoconazole in Soluplus®
are expected be less than 1% (w/w). With the increasing of temperature to 410K, both of systems
showed a homogeneous mixing with one single phase for almost the overall range, hence, 413K
(140°C) was set up as the processing temperature for the hot melt extrusion.
2. 2. 4 Estimation of miscibility and solubility of drugs in polymers
The term “solubility” here is referred to the concept in the basic thermodynamics theory,
which is the equilibrium parameter at a state where the chemical potential of solute equals to the
chemical potential of solvent. On the other hand, miscibility is termed in polymer physics for
polymer blends[103], which are usually in a stable amorphous state, and was further applied in
small molecule and polymer systems. It is worth to point out that if the drugs are in a meta-stable
amorphous state, they will always tend to recrystallize to the stable crystalline state, in other
words, to reach the equilibrium solubility of drugs in the polymer. From the last decade,
numerous approaches, including melting point depression[109-112], solubility parameters[98],
determining the solubility of drugs in the monomers[109], have been proposed to theoretically or
practically predict the miscibility and solubility of poorly water-soluble compounds in different
types of polymers. However, it is still difficult to measure the solubility of drugs in polymers at
normal storage temperature, especially the temperature close or below Tg, since it involves not
only the thermodynamic concerns but also the kinetics of phase separation and molecular
mobility[145]. It is commonly accepted that the equilibrium solubility of drug within polymers
only could be extrapolated or calculated by modeling. Most of the studies that tried to study the
miscibility or solubility of solid dispersions are based on thermal analysis, generally using DSC,
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while few drawbacks are associated with this technique. 1), any separated domain size below
about 30nm could be not discriminated by DSC[147]; 2) the miscibility may be affected by the
experimental condition during the heating process in DSC[148]. Beyond the traditional thermal
analysis, few other methods were applied to predict the miscibility of solid dispersion. Pair
Distribution Function (PDF), a computational method which is extrapolated from XRD pattern,
has been introduced by several research groups [149-152]. It represents the interatomic distance
which is the fingerprint of a certain solid and has been demonstrated capable to predict the
miscibility by comparison of the PDF pattern of individual amorphous component with their
final dispersion. It could be inferred that two components are miscible if the PDF pattern of the
solid dispersion cannot be derived from their individual patterns. Recently, solid state nuclear
magnetic resonance (SSNMR) was utilized to assess the miscibility of solid dispersions [153157]. It is pointed out that the phenomena, short-range dipolar coupling and longer-range spin
diffusion, are the fundamentals of feasibility of this techniques[154]. Rheological method was
also utilized to investigate the solubility of drug in polymer. Yang and the co-researchers
successfully determine acetaminophen's solubility in poly(ethylene oxide) by a combination of
rheological method and thermal analysis.[158].
2. 2. 5 Comparison of theoretical and practical Tg of solid dispersions
The glass transition temperature is an important characteristic of polymers, and it is
generally recognized that the Tg is not a real thermodynamic parameter, neither a first-order nor
second-order transition[90, 94]. Instead, it represents a temperature region by a single value
similar to the melting point temperature (Tm)[159]. The molecular mobility and the molecule
relaxation are condensed at the temperature below Tg, in contrast, the viscosity of polymer will
increase. Beyond the commonly used thermal analysis, other techniques, based on various
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mechanisms, were also applied to measure the glass transition temperature, including
dilatometry[90], thermo-mechanical analysis (TMA)[160], dynamic mechanical analysis
(DMA)[161], and dielectric analysis (DEA)[162], resulting in the different Tg values.
Information like miscibility could be extrapolated from the Tg value, thus, it is meaningful to be
able to theoretically predict the Tg for the early development of solid dispersion. To date, a few
empirical methods are proposed to estimate the Tg of binary mixture[137-139, 159, 163], and
among of which, Fox equation[137], Gordon-Taylor equation[138] and the Couchman-Karasz
equation[139] were applied most often. The glass transition temperature of Soluplus, felodipine,
and ketoconazole was determined as 68, 42.95 and 44.92°C, respectively (Table 2-1). Figure 2-6
illustrated the difference between theoretical and practical Tg of felodipine-Soluplus® solid
dispersions.
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Figure 2-6: Experimental vs theoretical Tg of FEL-SOL system
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All of the felodipine-Soluplus® solid dispersions demonstrated a single Tg (Figure 2.7),
which indicates a possible homogeneous miscible system. However, it is not robust enough to
conclude as a miscible system [152, 164].

Figure 2-7: DSC of FEL-SOL solid dispersions

The practical Tgs of felodipine-Soluplus® solid dispersions are significantly below the
theoretical ones. The discrepancy may be due to the limitation of the empirical methods which
are based on volume additivity and assumes no interactions between drug and polymer. Strong
intermolecular interactions, for instance, hydrogen-bonding, hydrophobic interactions, polar
interactions, and ionic interactions, would attribute to the difference between predicted and
practical values. A recently published review from Pinal[165]pointed out that in addition to the
drawbacks mentioned above, the contribution from the entropy of mixing was also ignored in
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those empirical equations. Moreover, it is also noteworthy considering the fact that T g is a
kinetically controlled phenomenon, in other word, the experimental condition will have an effect
on the final Tg obtained. The readers are recommended to refer the recent review from Baird and
Taylor for more details[166]. Contrast to felodipine-Soluplus® systems, two separated Tgs were
detected in all the ketoconazole-Soluplus® systems except the 10% KTZ loading solid dispersion
(listed as Table 2-2), indicating a phase separation occurred. As expected, the first Tg
corresponding to the amorphous ketoconazole was decreasing while the second Tg
corresponding to the melting point of ketoconazole was increasing with the increasing of KTZ
loading.
Table 2-2: Theoretical and experimental Tgs (°C) of ketoconazole-Soluplus® solid dispersions
KTZ (%)

Fox

G-T

C-K

Experimental

10

64.68

65.16

67.13

53.94

30

58.92

59.90

64.97

51.66, 123.90

50

54.10

55.13

61.99

42.33, 128.79

60

51.98

52.90

60.02

38.01, 137.44

70

50.01

50.77

57.59

35.83, 137.99
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CHAPTER 3
SOLUPLUS® AS A POLYMERIC CARRIER FOR SOLUBILITY ENHANCEMENT OF
POORLY WATER-SOLUBLE COMPOUNDS
3. 1 Methods
3. 1. 1 Solubility Parameter Calculation
The solubility parameter δ was calculated using Hoy and Hoftyzer/Van Krevelen method,
respectively, since both methods provide the same accuracy level (10%). The average value from
the two methods was used to estimate the drug-polymer miscibility as recommended[94]. To
determine the solubility parameter of Soluplus®, which is comprised of polyvinyl caprolactam polyvinyl acetate - polyethylene glycol in a ratio of 57:30:13, the number average of the three
monomers was calculated.
3. 1. 2 Differential Scanning Calorimetry (DSC)
The solubility of felodipine in Soluplus® matrix was predicted by DSC using a PerkinElmer Diamond DSC instrument (Norwalk, CT). Approximately 5-7 mg binary physical
mixtures containing felodipine varied from 10-100% were weighed and sealed into an aluminum
pan. Samples were heated from 30 to 180°C at various rump rates of 10, 20, 50 and 100°C/min.
The enthalpy of fusion of felodipine was recorded and plotted versus the concentration. The
extrudates were only subjected to a heating rate of 10°C/min. The instrument was calibrated with
indium and zinc before test. Nitrogen was used as purge gas at a flow rate of 20 mL/min. All the
experiments were triplicated.
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3. 1. 3 Hot-Melt Extrusion
A batch size of 50 g physical mixtures containing 10, 30 and 50% FEL were initially
sieved with USP 60 mesh and mixed in a V-cone blender (MaxiBlendTM, GlobePharma, North
Brunswick, NJ, USA) at 50 rpm for 15 min and further extruded with a co-rotating twin-screw
extruder (16 mm Prism EuroLab, ThermoFisher Scientific, Stone, UK) into uniform rods at an
extrusion temperature of 140°C and a screw speed of 100 rpm. Afterwards, part of the rods was
milled into fine powders using a laboratory grinder, and the rest was kept in refrigerator properly
until further study.
3. 1. 4 Phase Solubility Determination
Excess amount of felodipine (approximately 20 mg) was added to 20 mL vials containing
either purified water or pH 6.8 phosphate buffer (with or without pre-dissolved Soluplus®), the
concentration of Soluplus® varied from 0-1000 µg/mL (0, 10, 50, 100, 250, 500 and 1000 µg/mL,
respectively). The samples were placed into a Precision Reciprocal Shaking Bath (ThermoFisher
Scientific, Stone, UK) at 37°C and shaken at a speed of 80 rpm for 24 hours to achieve the
equilibrium. Afterwards, the samples were filtered through a 0.45 μm Nylon filter membrane
(Whatman, Piscataway, NJ) and further analyzed using HPLC at a λmax of 238 nm.
3. 1. 5 Particle Size Analysis
The samples from the phase solubility study were further subjected to particle size
analysis using a Zetasizer Nano ZS Zen3600 (Malvern Instrument, Inc. UK). Mean particle size
and the polydispersity index (PdI) were determined at 37°C backscatter detection in disposable
folded capillary clear cells. A He–Ne laser of 633 nm was utilized to obtain the data, and the
particle size analysis data was evaluated using volume distribution.
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3. 1. 6 Drug Release Studies
All the extrudates were subjected to in vitro dissolution studies utilizing a Hanson SR8plus™ dissolution test station (Hanson Research Corporation, Chatsworth, CA) operated at 100
rpm paddle speed. The extrudates were weighed precisely equivalence to 20mg FEL and filled
into size#1 gelatin capsules. These capsules were placed in sinkers and added to the dissolution
vessel. Two types of dissolution medium were utilized: 1) 500 mL pH 6.8 phosphate buffer, 2)
500 mL pH 6.8 phosphate buffer with pre-dissolved Soluplus® (250 and 500 μg/mL,
respectively). At pre-determined time intervals, 1.5 mL samples were removed from the
dissolution vessels and replaced with an equal volume of fresh dissolution medium. These
collected samples were immediately filtered using 13 mm PTFE membrane filters (Whatman,
Piscataway, NJ) with a pore size of 0.2 µm and analyzed using HPLC at a λmax of 238 nm.
Experiments were performed in triplicate and the mean values were compared.
3. 1. 7 Polarized Light Microscopy (PLM)
The optical properties of pure felodipine, Soluplus®, and extrudates were observed at
room temperature using a Nikon Eclipse E600 Pol microscope equipped with a Nikon DS-Fi 1
camera. Images were analyzed using NIS-Elements BR 3.2 software. In addition, the extrudates
were also exposed to dissolution medium (pH 6.8 phosphate buffer with or without pre-dissolved
Soluplus®), and observed under polarized light to understand the dissolution behavior.
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3. 1. 8 FT-IR Spectroscopy (FT-IR)
The spectra of FEL, SOL, and extrudates were obtained on a PerkinElmer Spectrum 100
FT-IR Spectrometer, equipped with the universal ATR accessory, in the range of 4000-650 cm-1,
using a resolution of 1 cm-1.
3. 1. 9 Raman Spectroscopy
The excitation sources employed for Raman spectroscopy were the 514.5 nm line and
647 nm line from a Stabilite 2018 Kr/Ar mixed-gas ion laser. The spectra were collected in the
range of 50-3600 cm-1 using a Jobin-Yvon Ramanor HG2-S Raman spectrometer with two 1800
grooves/mm gratings and a thermoelectrically cooled (-30°C) photomultiplier tube detector as
previously reported[167]. A scan speed of 2 cm-1/s was employed for spectra shown. Spectra
were obtained for the solid state of felodipine and Soluplus® as well as the extrudates.
3. 1. 10 Theoretical Methods
Calculations were performed using the Gaussian 09 package (Revision A.1 ed.; Gaussian,
Inc.: Wallingford CT, 2009). The optimized equilibrium geometry, vibrational frequencies, and
Raman intensities of Felodipine were determined using the B3LYP density functional with the 6311+g (d, p) basis set. Simulated spectra were constructed with a custom program developed
with National Instruments LabView as reported[167].
3. 1. 11 X-ray diffraction (XRD)
XRD studies were performed on a powder X-ray diffraction apparatus (Bruker AXS,
Madison, WI) using CuKα radiation at 40 mA and 40 kV. The samples of interest were analyzed
in the diffraction angles range of 5–35° (2θ) at a scan rate of 2°/min, with a scanning step of
0.05°. All of experiments were triplicated.
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3. 1. 12 Scanning Electron Microscopy (SEM)
The morphology of samples was determined using a JEOL JSM-5600 SEM at an
accelerating voltage of 5kV equipped with JSM 5000 software. Samples of interest were coated
with gold utilizing a Hummer 6.2 sputtering system for 10min before observation.
3. 2 Results and Discussion
3. 2. 1 Solubility parameter calculation
It is crucial to measure the solubility/miscibility of drug in polymer when developing
amorphous solid dispersions since it will provide useful information regarding the proper
selection of drug loading along with the prediction of the stability of solid dispersions[88].
Solubility is generally recognized as a thermodynamic parameter at which moment the chemical
potential of the substance in the solvent equals to the chemical potential of substance precipitated
and the same concept could be used in drug-polymer systems[145]. The term of miscibility is
firstly introduced in the polymer blends[168], and further extrapolated to small molecule systems.
However, unlike the polymer blends, the amorphous drugs are usually metastable and tend to
recrystallize, resulting in a more complex situation to predict the miscibility. As mentioned
before, solubility parameter was applied to predict the miscibility of felodipine-Soluplus® in the
current study. The group contribution values of felodipine and the three monomers of Soluplus®
were listed in Table 3-1 to 3-8[94]. Consequently, the solubility parameter of felodipine was
calculated as 20.78 and 22.74, according to the Hoy and Hoftyzer/Van Krevelen method,
respectively. Meanwhile, the solubility parameter of Soluplus® was determined as 21.49 and
21.79, respectively. The solubility parameter of Soluplus® obtained by gas chromatography was
19.4[93], which is close to the average value 21.64 in this study, indicating the accuracy of this
method. It is well accepted that two substances are not miscible if the solubility parameter
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difference is larger than 10 MP1/2; to the contrast, good miscibility is expected when the
difference is less than 7 MP1/2, especially when the difference is less than 2 MP1/2[98]. However,
it is worth mentioning that solubility parameter only provides a simple theoretical pathway to
predict the miscibility of drug-polymer systems from the initial assessment standpoint, it is
always necessary to perform practical experiments to identify the miscibility of the drug-polymer
systems for formulation development. Nevertheless, it is clearly shown that the solubility
parameters of felodipine and Soluplus® are very close to each other (Table 3-9), which indicated
the likelihood of drug-polymer miscibility.
Table 3-1: Group contribution of felodipine using Hoftyzer/Van Krevelen method
Structure group

No.

(MJ/m3)½ Ehi

Fdi

Fpi

V

(MJ/m3)½*

*mol-1

(J/mol)

(cm3*mol-1)

mol-1
–CH3

4

420

0

0

33.5

–CH2–

1

270

0

0

16.1

>CH–

1

80

0

0

-1

=C<

4

70

0

0

-5.5

–Cl

2

450

550

400

26

–COO–

2

390

490

7000

18

–NH–

1

160

210

3100

4.5

Ring

1

190

0

0

16

Phenylene (o, m, p)

1

1270

110

0

33.4
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Table 3-2: Group contribution of felodipine using Hoy method
Structure group

No.

ΔT, i*

FT, i
(MJ/m3)½ *mol-1

V
(cm3*mol-1)

–CH3

4

303.5

0.023

21.55

–CH2–

1

269

0.02

15.55

>CH–

1

176

0.012

9.56

=C<

4

173

0

7.18

–Cl

2

330

0.017

19.5

–COO–

2

640

0.047

23.7

–NH–

1

368

0.031

11

Ring (6 membered)

1

-48

0

----

Phenylene (o, m, p)

1

20.2

0

----

CHar.

3

241

0.011

13.42

Car.

3

201

0.011

7.42

Table 3-3: Group contribution of PEG6000 using Hoftyzer/Van Krevelen method
Structure group

No.

(MJ/m3)½ Ehi

Fdi

Fpi

V

(MJ/m3)½

*mol-1

(J/mol)

(cm3*mol-1)

*mol-1
–CH2–

2

270

0

0

16.1

–OH–

2

210

500

20000

10
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Table 3-4: Group contribution of Vinyl Acetate using Hoftyzer/Van Krevelen method
Structure group

No.

(MJ/m3)½ Ehi

Fdi

Fpi

V

(MJ/m3)½

*mol-1

(J/mol)

(cm3*mol-1)

*mol-1
–CH3

1

420

0

0

33.5

–COO–

1

390

490

7000

18

=CH–

1

200

0

0

13.5

=CH2

1

400

0

0

28.5

Table 3-5: Group contribution of Vinyl Caprolactam using Hoftyzer/Van Krevelen method
Structure group

No.

(MJ/m3)½ Ehi

Fdi

Fpi

V

(MJ/m3)½

*mol-1

(J/mol)

(cm3*mol-1)

*mol-1
>N–

1

20

800

5000

-9

–CO–

1

290

770

2000

10.8

=CH–

1

200

0

0

13.5

=CH2

1

400

0

0

28.5

–CH2–

5

270

0

0

16.1

Ring

1

190

---

---

16

Table 3-6: Group contribution of PEG6000 using Hoy method
Structure group

No.

ΔT, i(P)

FT, i
(MJ/m3)½ *mol-1

V
(cm3*mol-1)

–CH2–

2

269

0.02

15.55

–OH–

2

675

0.049

12.45
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Table 3-7: Group contribution of Vinyl Acetate using Hoy method
Structure group

No.

ΔT, i(P)

FT, i
(MJ/m3)½ *mol-1

V
(cm3*mol-1)

–CH3

1

303.5

0.022

21.55

–COO–

1

640

0.05

23.7

=CH–

1

249

0.0185

13.18

=CH2

1

259

0.018

19.17

Table 3-8: Group contribution of Vinyl Caprolactam using Hoy method
Structure group

No.

ΔT, i(P)

FT, i
(MJ/m3)½ *mol-1

V
(cm3*mol-1)

>N–

1

125

0.008

12.14

–CO–

1

538

0.04

17.3

=CH–

1

249

0.0185

13.18

=CH2

1

259

0.018

19.17

–CH2–

5

269

0.02

15.55

Ring (7-membered)

1

92

0.007

---

Table 3-9: Summary of the calculated parameters of felodipine, monomers and Soluplus®
FEL

PVC

PVA

PEG

SOL

Hoy

20.78

19.45

19.48

35.08

21.49

H-V

22.74

20.43

18.16

36.14

21.79

Ave.

21.76

---

---

---

21.64
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3. 2. 2 Differential Scanning Calorimetry (DSC) Analysis
Figure 3-1 demonstrated the thermal behavior of pure felodipine under different heating
rate. The peak magnitude increased with the heating rate, which is due to the alternation of flow
of energy measured by DSC [142, 169].

Figure 3-1: DSC of felodipine at different heating rate
Numerous approaches have been proposed to determine the solubility of drug within
polymer in solid state, either theoretically or practically, based on different mechanisms, and one
of them is to utilize the enthalpy of fusion[109, 142, 158, 170-176]. The enthalpy of fusion is
generally defined as the heat needed to convert the substance from solid to liquid state without
temperature increasing[177], and it was introduced to calculated the drug solubility by Theeuwes
et al. based on the mechanism that the dissolved drug has no contribution to the endothermic
event[174]. Therefore, by plotting the enthalpy of fusion versus the drug loading concentration,
the intercept in X-axis would be theoretical solubility of the drug within the polymer[174].
Moreover, the scan rate of DSC is reported to affect the thermal events by several studies [142,
47

176], as a faster scan rate will improve sensitivity while losing resolution and vice versa. The
values of enthalpy of fusion of felodipine were recorded and plotted versus concentration in
Figure 3-2; a good linear correlation was obtained for each scan rate. Subsequently, the predicted
solubility of felodipine in Soluplus® matrix was determined as 9.24, 9.86, 6.23 and 6.28%,
respectively. The solubility measured at a higher scan rate is lower to which determined at a
slower scan rate, this phenomenon is similar as the study reported by Gramaglia et.al[142],
which is possibly due to that a slow scan rate will provide more time for the two components to
achieve completely mixing.

Figure 3-2: Plot of ΔH versus concentration at different heating rate
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3. 2. 3 Phase Solubility Determination
Figure 3-3a demonstrated the phase solubility of felodipine in aqueous solutions with or
without pre-dissolved Soluplus®. The solubility of felodipine could not be detected in neither
medium without pre-dissolved Soluplus® which is due to the low aqueous solubility of
crystalline felodipine. With the increasing of concentration of Soluplus® in water, the solubility
of felodipine was enhanced up to 20.44 µg/ml which is attributed to the solubilizing effect of the
amphiphilic structure of Soluplus® and the formation of drug polymer conjugate, however, the
solubility of felodipine in the phosphate buffer with Soluplus® was comparatively lower than the
ones in water. Moreover, the particle size analysis of the blank Soluplus® solution demonstrated
that Soluplus® can form micelles in both water and phosphate buffer in the range of 70-80 nm,
and the particle size of the micelles kept constant once its concentration was above 10 μg/ml,
which is consistent with the reported critical micelles concentration (CMC) of Soluplus® in water
at 37°C as 7.9 μg/ml [93] (Table 3-10). Interestingly, with the addition of felodipine, the particle
size was observed to reduce to 50-60 nm associated with a very narrow particle size distribution
indicating felodipine was embedded into the micelles. Therefore, it would not be surprised to
observe solubility enhancement with nano-sized particles, and the reduction of particle size is
most probably due to the intermolecular interaction, for instance, hydrogen bonding, between the
two components, which can attract each other.
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Figure 3-3: Phase solubility of felodipine in aqueous solutions (a), Particle size distribution of
felodipine in water with 1000 μg/ml Soluplus® (b), Particle size distribution of felodipine in
phosphate buffer (pH=6.8) with 1000 μg/ml Soluplus® (c)
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Table 3-10: Particle size analysis (Mean ± SD, d.nm) Solution A: phosphate buffer with
Soluplus®, solution B: water with Soluplus®, solution C: felodipine in phosphate buffer with
Soluplus®, solution D: felodipine in water with Soluplus®
Conc. of Soluplus® (μg/mL)

Solution A

Solution B

Solution C

Solution D

0

---

---

---

---

10

78.75±1.23

67.12±1.31

65.32±1.65

62.29±2.01

50

78.98±2.19

62.89±1.45

67.58±2.01

62.17±1.98

100

73.47±1.87

64.30±1.21

67.19±1.11

61.16±1.78

250

70.74±2.23

65.25±1.63

66.60±1.32

61.56±1.89

500

71.25±0.98

63.06±1.99

63.30±1.47

60.87±1.45

1000

72.29±1.34

63.17±1.12

62.80±1.32

60.98±1.89

3. 2. 4 Dissolution Results
The dissolution profiles of felodipine-Soluplus® solid dispersions as well as the pure
felodipine were shown in Figure 3-4. The drug loading has a clear effect on the solubility profile,
and supersaturation was generated in the formulation containing 10% felodipine. The solubility
of felodipine was increased to approximately 12 µg/ml in 30min followed a precipitation which
is possibly attributed to the metastable amorphous state of felodipine in the matrix. Meanwhile,
SDs with 30% and 50% felodipine showed a slight enhancement of solubility. It was illustrated
by Friesen et al, that the physical properties of drug substance, for instance, the melting point
temperature, glass transition temperature and LogP value, would affect the drug loading in the
formulations[178]. If Tm/Tg value larger than 1.4 associated with a LogP value less than 6, the
compounds would have a tendency to recrystallize from the amorphous state and limit a drug
loading between 10-35% in the formulation. In this case, the Tm/Tg value of felodipine was
determined as 1.87 and the LogP value is 4.83[179], therefore, the dissolution behavior of
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felodipine is expected.

Formulation scientists have been made great efforts to inhibit the

precipitation of supersaturated drug delivery systems and maintain a sufficient period of high
solubility by many approaches and one of the most important method is to form intermolecular
interaction with the aids of different excipients, for instance, polymers[180, 181],
surfactants[182], and

cyclodextrins[183]. Typically,

the precipitation

of drug from

supersaturation system consists two steps, nucleation and the following crystal growth process. It
is important to point out that the dissolved drug molecules have to overcome an energy barrier,
which is due to the interfacial tension between drug particles and dissolution medium, to form
aggregates (nucleation process), which can further grow to crystals, although the precipitation is
thermodynamically driven by supersaturation. Therefore, the energy barrier provides the
possibility to delay or prevent the nucleation process if it could be promoted high enough to
overcome and the supersaturation could remain in the metastable state for longer time.
Pharmaceutical excipients like polymers have been widely employed to stabilize the
supersaturation systems based on the mechanism of direct interaction between polymers and
drug particles and hydrogen bonding is the one observed most often. The active energy is
increased with the formation of hydrogen bonding, and furthermore, the polymers will compete
with the drug particles to absorb on the crystals or postpone the absorption by means of steric
effect, which will finally lead to a retarded crystal growth rate[114]. Clearly, the apparent
solubility of felodipine in all three solid dispersions was promoted and maintained in the
phosphate buffer with pre-dissolved Soluplus® (Figure 3-5). This phenomenon could be
explained that the pre-dissolved Soluplus® formed micelles itself which can embed the felodipine
resulting in a further enhancement of solubility. Moreover, the pre-dissolved Soluplus® could
also form intermolecular interaction with the dissolved felodipine molecules, which can delay
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the precipitation process. However, the amount of pre-dissolved Soluplus® studied here did not
make significant difference on the solubility enhancement effect.

Figure 3-4: Dissolution profile of felodipine-Soluplus solid dispersions in 500 mL pH 6.8
phosphate buffer

Figure 3-5: Dissolution profile of felodipine-Soluplus solid dispersions in 500 mL pH 6.8
phosphate buffer with pre-dissolved Soluplus® (250 and 500 μg/mL, respectively)
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3. 2. 5 DSC and XRD
The DSC thermograms of individual components along with solid dispersions of three
ratios were reported in Figure 3-6. No characteristic endothermic melting peak of felodipine was
observed which illustrated the amorphous state of felodipine in the structure. Moreover, in
addition with the single glass transition temperature (Tg), homogeneous solid dispersions were
obtained and which is expected to further benefit the physical stability of extrudates, however,
exceptions were also reported[152, 164]. Therefore, it is necessary to characterize the solid
dispersions utilizing other techniques.

Figure 3-6: DSC of felodipine-Soluplus solid dispersions
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XRD has been the thumb of rule to characterize the solid dispersion in the pharmaceutical
industry due to its excellent capacity to provide fingerprints and quantitative analysis of
substance[184]. No crystalline peaks were detected in the solid dispersions compared to the pure
felodipine indicating the possible amorphous state of drug (Figure 3-7).

Figure 3-7: XRD of pure felodipine, Soluplus® and FEL-SOL solid dispersions
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3. 2. 6 Polarized light microscopy
For crystalline materials, the molecules are regularly arranged, which usually results in
various refractive indices and finally turns into the exhibition of vivid color when the substances
are observed under polarized light. On the other hand, the molecules in amorphous substance are
randomly oriented, and only one principle refractive index is corresponded. Although cubic
crystals such as sodium chloride also have the same property as amorphous substance, they
rarely exist in organic materials. Therefore, the crystalline and amorphous states of substances
can be differentiated by polarized light due to the different optical properties and the absence of
birefringence is a strong evidence of the existence of amorphous state[185, 186]. In Figure 3-8b,
none of the SDs exhibited birefringence as contrasted to the crystalline felodipine (Figure 3-8a),
and the observation was also obtained for 10 and 50% SDs, which confirmed the amorphous
state of felodipine in the formulations. In addition, the SDs were also exposed to pH 6.8
phosphate buffer and observed to simulate the dissolution process. Interestingly, the particles of
10% felodipine solid dispersion slightly extended with a deduction of thickness during the period
of observation, which likely demonstrated that the solid dispersions already started to dissolve
into the medium, while no similar phenomenon was observed for 30% or 50% solid dispersion
(Figure 3-8c and 3-8d). This would be attributed to the higher apparently solubility of 10% solid
dispersions compared to the others.
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Figure 3-8: PLM images of crystalline felodipine (a), 30% felodipine-Soluplus® SD (b), 10%
felodipine-Soluplus® SD exposed to phosphate buffer at 0min (c), 10% felodipine-Soluplus® SD
exposed to phosphate buffer at 30min (d)
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3. 2. 7 Fourier transform infrared spectroscopy (FT-IR)
Felodipine was reported to be able to form hydrogen bonding with several types of
polymers containing hydrogen acceptor group while felodipine itself functions as a donor [187190]. As previously mentioned before, the delay of the precipitation of felodipine solid
dispersions was probably due to the intermolecular interaction with Soluplus®, therefore, FT-IR
and Raman Spectroscopy were conducted to prove the proposal. Crystalline felodipine
demonstrated a characteristic N-H stretch peak at around 3371 cm-1 (Figure 3-9), however, no NH stretch peak was detected solid dispersions of all three ratios which would possibly due to the
formation of hydrogen bond with the ketone group in Soluplus® structure.
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Figure 3-9: FT-IR spectra of felodipine, Soluplus® and SDs
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3. 2. 8 Raman spectroscopy
To date, Raman spectroscopy has been extensively applied in pharmaceutical researches
for both qualitative and quantitative purposes, and it was successfully utilized to determine the
hydrogen bonding [34, 151, 191-193]. Nollenberger et al. reported that felodipine has a
characteristic N-H stretch peak at 3375 cm-1 as well as a characteristic peak at 1639 cm-1 due to
the free carbonyl stretching[151]. Although the N-H stretch peak in felodipine was not obvious
in the Raman study here, attributed to the higher intensity of other molecular vibrations (Figure
3-10a), a Raman peak shift was clearly observed in the range of 1200-1700 cm-1, which is an
indication of potential intermolecular interaction (Figure 3-10b). Therefore, a theoretical
calculation of felodipine molecular vibration was conducted to further identify the corresponding
shifted peaks and consequently, C-H bending, N-H bending and an combination of C-C
stretching with N-H bending peak were confirmed associated with 8, 7 and 5 cm-1 wavelength
peak shift, respectively, which is indicative of the formation of hydrogen bonding (Figure 3-10c).
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Figure 3-10: Raman spectra of felodipine, Soluplus® and SDs in the range of 50-3600cm-1 (a),
Raman spectra of felodipine, Soluplus® and 50% SD in the range of 1200-1700 cm-1 (b),
Theoretical and practical Raman spectra of felodipine in the range of 1200-1700 cm-1 (c)

60

3. 2. 9 Scanning Electron Microscopy
SEM has been widely applied to characterize solid-state properties of substances in
pharmaceutical industry due to its high magnification and resolution[185]. The morphology of
the selected samples was evaluated in SEM studies. Soluplus® powders demonstrated spherical
shapes with smooth surface which indicates the amorphous state of the polymer (Figure 3-11a).
To the contrast, pure felodipine powders revealed a plate-like shape with edged surfaces,
attributed to the crystalline form (Figure 3-11b) [97]. For 10% felodipine solid dispersion, the
surface was also smooth indicating that the felodipine was in amorphous state and uniformly
distributed in the matrix, however, in the solid dispersions which contain 30 and 50% felodipine,
few species with the features of crystal felodipine were detected which can possibly contribute to
the phenomenon that no significant enhancement of solubility in these two solid dispersions
compared to pure felodipine (Figure 3-11c and d). In addition, the cross-section of the extruded
rods was also investigated. There is no difference between pure Soluplus® and 10% felodipineSoluplus® rods, which indicated felodipine molecularly dispersed into the matrix and the
formation of solid solution, to the contrary, few small felodipine crystals were also detected in
part of the 30 and 50% felodipine-Soluplus® rods, which is consistent with the observation of
extrudates surface; these small aggregates in the extrudates might also explain the lower
solubility of 30 and 50% extrudates (Figure 3-11e-g). And this discrepancy with XRD studies
was probably due to the detection limit of XRD (5% w/w)[88]
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Figure 3-11: SEM of Soluplus® (a), felodipine (b), crystalline features of 30% SD (c), smooth
surface of 50% SD (d)
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Figure 3-11: cross-section of Soluplus® rods (e), cross-section of 10% felodipine rods (f), crosssection of 30% felodipine rods (g)
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CHAPTER 4
INFLUENCE OF FORMULATION FACTORS AND PROCESSING PARAMETERS ON
KETOCONAZOLE-SOLUPLUS® MELT EXTRUDATES USING RESPONSE SURFACE
METHODOLOGY
4. 1 Methods
4. 1. 1 Solubility Parameter Calculation
The solubility parameter δ was calculated using Hoftyzer/Van Krevelen method, which
provides an accuracy level of 10% as mentioned previously[94]. To determine the solubility
parameter of Soluplus®, which is comprised of polyvinyl caprolactam-polyvinyl acetatepolyethylene glycol at a ratio of 57:30:13, the number average of the three monomers was
calculated.
4. 1. 2 Differential Scanning Calorimetry
The solubility of ketoconazole in Soluplus® matrix was predicted by DSC using a PerkinElmer Diamond DSC instrument (Norwalk, CT). Approximately 5-7 mg binary physical
mixtures containing 10-100% ketoconazole were weighed and sealed into an aluminum pan.
Samples were heated from 30 to 200°C at a ramp rate of 10°C/min, and cooled down from 200 to
30°C at a rate of 40°C/min followed a re-heating cycle to 200°C at a rate of 10°C/min. The
enthalpy of fusion of ketoconazole was recorded and plotted versus the concentration. The
extrudates were only subjected to the first heating cycle. The instrument was calibrated with
indium and zinc before testing. Nitrogen was used as purge gas at a flow rate of 20mL/min. All
the experiments were performed in triplicate.
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4. 1. 3 Central Composite Design
A central composite design (CCD) based response surface methodology (RSM) was
created using Design-Expert® 8.0 (Stat-Ease, Inc.), with three independent variables (% drug
load, screw speed and temperature) and two dependent variables (post-extrusion drug content
and % drug release at 15min).
4. 1. 4 Hot Melt Extrusion
The drug-polymer physical mixtures were prepared at pre-determined drug concentration.
The two components were initially sieved with USP 60 mesh and further mixed in a V-cone
blender (MaxiBlendTM, GlobePharma, North Brunswick, NJ, USA) at 50 rpm for 15 min. The
mixtures were extruded into uniform rods using a ThermoFisher Scientific HAAKE MiniLab II.
The extruded rods were milled into powder using a laboratory grinder.
4. 1. 5 Drug Content Analysis
Approximately 20 mg of the physical mixtures or powdered extrudates were weighed and
dissolved in 20 mL methanol. The solution was then diluted 10 times with methanol. The
samples were filtered through 13 mm PTFE membrane filters (Whatman, Piscataway, NJ) and
analyzed utilizing a HPLC at a wavelength of 231 nm. The mobile phase consisted of 25 mM
phosphate buffer and acetonitrile at a ratio of 4:6, and the pH was adjusted to 4.5 with
phosphoric acid.
4. 1. 6 In Vitro Dissolution Studies
Extrudates containing ketoconazole equivalent to 20 mg were filled into capsules and
subjected to dissolution studies using a Hanson SR8-Plus dissolution test system according to
USP 31 apparatus 2, (0.1N HCl pH 1.2, 75 rpm, 37±0.5°C). 1.5 mL samples were collected
precisely at pre-determined interval and replaced with equal amount of fresh dissolution medium.

65

The withdrawn samples were immediately filtered through a 0.2 µm, 13 mm PTFE membrane
filters (Whatman, Piscataway, NJ) and analyzed using the same method utilized for drug content
analysis.
4. 1. 7 Fourier Transform Infrared Spectroscopy (FT-IR)
Fourier transform infrared spectroscopy (FT-IR) studies were conducted on a
PerkinElmer Spectrum 100 FT-IR Spectrometer, equipped with the universal ATR accessory, in
the range of 4000-650 cm-1, using a resolution of 1 cm-1. All the experiments were performed in
triplicate.
4. 1. 8 Stability
The extrudates were filled into sealed borosilicate glass vials and stored under 25°C/60%
RH and 40°C/75% RH conditions per ICH guidelines. At pre-determined time interval, samples
were subjected to DSC, content analysis, and dissolution studies to evaluate the physical and
chemical stability.
4. 2 Results and discussion
4. 2. 1 Solubility Parameter Calculation
The group contribution of ketoconazole is listed in Table 4-1, and the solubility
parameters was further determined as 26.51. It is well accepted that two materials are likely to be
miscible if the difference of solubility parameters is less than 7 MP1/2, and in contrast,
immiscibility is expected if the difference is larger than 10 MP1/2[98]. As calculated before, the
solubility parameter of Soluplus® is 21.64, therefore, KTZ and SOL are expected to be partially,
if not completely, miscible.
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Table 4-1: Group contribution of ketoconazole using Hoftyzer/Van Krevelen method
Structure group

No.

Fdi

Fpi

Ehi

(MJ/m3)½ ·mol- (MJ/m3)½ ·mol- (J/mol)
1

1

V
(cm3·mol-1)

–CH3

1

420

0

0

33.5

–CH2–

6

270

0

0

16.1

=CH–

3

200

0

0

13.5

>C<

2

-70

0

0

-19.2

–Cl

2

450

550

400

26

–CO–

1

290

770

2000

10.8

–N<

3

20

800

5000

-9

–O–

3

100

400

3000

3.8

–N=

1

0

0

0

5

Ring

3

190

0

0

16

Phenylene (o, m, p)

2

1270

110

0

33.4

4. 2. 2 Differential Scanning Calorimetry
As previously mentioned, it is challenging to estimate the solubility of a drug within a
polymer in the solid state; however, several approaches have been demonstrated to either
theoretically or practically determine the drug’s solubility in the polymer. One such method is to
utilize the enthalpy of fusion[110, 141, 142, 158, 170-175, 194]. The enthalpy of fusion is
generally defined as the heat needed to convert the substance from solid to liquid state without
increasing the temperature[177], and it was introduced to calculate the drug solubility by
Theeuwes et al. based on the assumption that the dissolved drug has no contribution to the
endothermic event. Therefore, by plotting the enthalpy of fusion versus the drug loading
concentration, the intercept in the X-axis would be the theoretical solubility of the drug within
the polymer [174]. As presented in Figure 4-1a, Ketoconazole has a characteristic melting peak
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at 146°C, and a glass transition temperature of 42°C while in the amorphous phase was
determined using the second heating cycle (Figure 4-1b). The variation from the Tg value in
Chapter 2 is most probably due to experimental related characteristics of Tg. Moreover, with an
increase in the concentration of Soluplus®, the height of the melting peak decreased.
Interestingly, a small hump around 62°C was also observed when the concentration of
ketoconazole reduced to 40% or less, which was possibly attributed to the Tg value of small
amount of KTZ-SOL solid dispersion when the physical mixtures prepared. No endothermic
peak was observed in the second heating cycle for all binary mixtures, which indicated that the
drug was converted into its amorphous phase. Furthermore, the solubility of ketoconazole in
Soluplus® matrix was determined as ~5% (Figure 4-2).

68

Figure 4-1: First heating cycle of DSC (a), Second heating cycle of DSC (b)
(From the top to bottom: 100, 90, 80, 70, 60, 50, 40, 30, 20, and 10% KTZ or KTZ-SOL
physical mixtures)
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Figure 4-2: Enthalpy of fusion versus ketoconazole concentration
4. 2. 3 Central Composite Design
Processing parameters such as screw design, screw speed, feeding rate or process
temperature have been demonstrated to have influences on the properties of extrudates in many
studies [195-197]. However, it is also not unusual to find that the processing parameters have
little or no effect on the properties of formulation [198]. Therefore, whether these parameters
would affect the properties of the formulation needs to be considered on a case-by-case basis.
Twenty formulations containing ketoconazole and Soluplus® including six center points (marked
in yellow) were generated under a central composite design (Table 4-2), in which, drug loading
(A), screw speed (B), and processing temperature (C) are the independent variables, while post
extrusion content as well as drug release percentage at 15min are the dependent variables.
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Table 4-2: Experimental Design
Std

Run

Factor 1

Factor 2

Factor 3

A: Drug loading (%)

B: Screw speed (RPM)

C: Temperature (°C)

6

1

36

65

112

7

2

24

65

148

1

3

24

35

112

17

4

30

50

130

13

5

30

25

130

16

6

30

50

130

4

7

36

35

148

11

8

30

50

100

19

9

30

50

130

14

10

30

75

130

12

11

30

50

160

3

12

24

35

148

8

13

36

65

148

10

14

40

50

130

5

15

24

65

112

18

16

30

50

130

9

17

20

50

130

2

18

36

35

112

15

19

30

50

130

20

20

30

50

130
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4. 2. 4 Statistical analysis
In the dissolution studies, all of twenty formulations demonstrated approximately 100%
release at 45min, compared to less than 20% release of the pure drug, which demonstrated
solubility enhancement of ketoconazole. The overall results were shown in Figure 4-3, and
further subjected to analysis of variance (ANOVA). Both of the two responses (post extrusion
content and % drug release at 15min) fit into the response surface quadratic model appropriately.
This is indicated by the p-value of the model and lack of fit (0.0002, 0.0647) and (0.0005,
0.0517), respectively.

Figure 4-3: Overall results of twenty KTZ-SOL formulations

72

The post extrusion content can be expressed in the equation below,
Post extrusion content = 101.15+8.29*A-3.60*B+2.97*C+2.77*A*B0.38*A*C+2.07*B*C-9.88A2-0.20B2-2.16C2………………………………………Equation 4-1
Whereas drug loading has the most significant effect (p<0.0001) on the post-extrusion
content (Figure 4-4). The two opposite coefficients of A and A2 (8.29 and -9.88, respectively),
imply that drug loading has a dual influence on the post extrusion content, and an optimized
value will exist. It is not surprising to obtain a high content while the drug loading is high. On
the other hand, when drug loading is very low, an acceptable post extrusion content could also be
obtained which is possibly attributed to the more homogeneous mixing. Temperature and screw
speed also had partial effect on the content. A slower screw speed is associated with a prolonged
residence time in the extruder, while a higher processing temperature would reduce the viscosity
of polymer which will also be beneficial for mixing.

Figure 4-4: ANOVA for response surface quadratic model of post extrusion content
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Similar to post extrusion content, the % Drug release at 15min can also be expressed by
the following equation:
% Drug release at 15min = 73.08-2.42*A-3.98*B+6.74*C+3.01*A*B-3.53*A*C0.88*B*C-6.29A2-2.28B2-5.80C2………………………………………………………………………………..Equation 4-2
Whereas all of the three independent factors affected the % drug dissolution at 15
minutes which is indicated by the p-value of A2 (0.0005), B (0.0108), C (0.0004) and C2 (0.0009)
(Figure 4-5). The negative coefficient -6.29 of A2 indicates that a high drug loading will retard
the release of ketoconazole, which is due to the reduction of hydrophilic polymer in the
formulation. Meanwhile, the negative coefficient -3.98 of B illustrates that slower screw speed
will provide a more sufficient time for mixing which will turn into a faster release. However, it is
surprising to find out opposite coefficients of C and C2 which demonstrate that temperature
might have a dual effect on the % release at 15min.

Figure 4-5: ANOVA for response surface quadratic model of % release at 15min
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The actual values of both post extrusion responses, content and % release at 15 min, laid
beside the predicted values (straight line in Figure 4-6 a and b) indicates the robustness of the
experimental design.

Figure 4-6: Predicted values vs actual values post extrusion content (a), % release at 15min (b)
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As a result, the formulation parameters were further optimized as: 29.8% drug loading
extruded at a temperature of 140°C and screw speed of 31 rpm with highest desirability of 0.489
(Figure 4-7) a predicted post processing content of 104.86% (Figure 4-8a) and 77.19% (Figure 48b) release at 15min on the criteria of maximizing drug loading, post extrusion content and %
release at 15min (The cut-off values of post extrusion content and % release at 15 min were set
up as 95% and 70%, respectively) while maintaining extrusion temperature and screw speed in
the range of the design space.

Figure 4-7: 3D contour of desirability
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Figure 4-8: 3D contour of KTZ post extrusion content (a), % release at 15min (b)
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In order to validate the optimized model, three repeated batches were conducted under
the conditions stated above, and the results were consistent with the predicted values which
demonstrated the robustness of this model (Table 4-3 and Figure 4-9).
Table 4-3: Predicted value vs actual value of optimized formulation
Response

Predicted Value

Actual Value

Bias (%)

Post extrusion content (%)

104.86

97.68±4.38

6.85

Release at 15min (%)

77.19

72.80±1.31

5.69

Bias= (Predicted Value-Actual Value)/Predicted Value ×100
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Figure 4-9: Dissolution profile of optimized formulation containing 29.8% KTZ
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4. 2. 5 Fourier transform infrared spectroscopy
Intermolecular interactions, for instance hydrogen bonding, are important in solid
dispersion systems which have been demonstrated to benefit the physical stability. However, due
to the fact that no hydrogen donor is presented in the structure of KTZ, it is not expected that
hydrogen bonding would be observed nor other intermolecular interactions between KTZ and
SOL. In order to confirm the assumption, FT-IR studies were conducted on individual
component and the extrudates. As shown in Figure 4-10, the spectrum of extrudates is a
collection of the two components’ patterns and no sign of hydrogen bonding was detected.
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Figure 4-10: FT-IR spectra of KTZ, SOL and Extrudates
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4. 2. 6 Scanning electron microscopy (SEM)
The morphology of the Ketoconazole-Soluplus® solid dispersions was examined by SEM
study (Figure 4-11a-d). This technique provided direct visual information about the samples. The
pure crystalline ketoconazole demonstrated a plate-like shape with rough surfaces, while the
Soluplus® particles appeared spherical in shape. Meanwhile, the extrudates revealed a smooth
surface which indicated that ketoconazole was in the amorphous state within the matrix [97].
Furthermore, since all the particles under observation demonstrated a similar morphology, it
could be extrapolated that the drug was uniformly distributed into the matrix, which indicates
good miscibility between drug and polymer.

Figure 4-11: SEM of KTZ ×330 magnification (a), SEM of KTZ ×1300 magnification (b), SEM
of SOL (c), SEM of optimized extrudates (d)
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4. 2. 7 Stability Test
Stability is one of the most crucial concerns for any pharmaceutical development process,
and in regards to the amorphous solid dispersions, the drugs could be less physically or
chemically stable than crystalline materials due to being in a higher energy state. Moreover,
moisture and temperature are the most common factors which can induce the stability issues
[199-201]. Hence, the optimized formulation was stored into two temperature/moisture
conditions to evaluate both the physical and chemical stability. No sign of re-crystallization or
phase separation was determined in the DSC thermograms (Figure 4-12) which was indicative of
a good physical stability. Additionly, all the drug content tests performed on the stability samples
were above 95% and all the samples demonstrated similar dissolution profile demonstrating the
samples chemically stable (Figure 4-13 &14).

Figure 4-12: DSC of crystalline KTZ, fresh extrudates, stability samples stored at 25°C/60% RH
and 40°C/75% RH (3 month point)
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Figure 4-13: In vitro dissolution of crystalline KTZ, stability samples stored at 25°C/60% RH
and 40°C/75% RH (1, 2 and 3 month point)
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Figure 4-14: KTZ content of fresh extrudates, stability samples stored at 25°C/60% RH and
40°C/75% RH (1, 2 and 3 month point)
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CHAPTER 5
SOLUBILITY ENHANCEMENT AND PRECIPITATION INHIBITION OF
PACLITAXEL USING HOT MELT EXTRUSION TECHNOLOGY
5. 1 Methods
5. 1. 1 Phase solubility determination
An excess amount of paclitaxel (approximately 1mg) was added to 20mL vials containing
pH 1.2 hydrochloric acid, pH 4.0 critic acid buffer, pH 6.8 and 7.4 phosphate buffer,
respectively. The samples were placed into a Precision Reciprocal Shaking Bath (ThermoFisher
Scientific, Stone, UK) at 37°C and shaken at a speed of 80rpm for 48 hours to achieve
equilibrium. The samples were then filtered through a 0.45 μm Nylon filter membrane
(Whatman, Piscataway, NJ) and analyzed using HPLC at a λmax of 230 nm.
5. 1. 2 Preparation of solid dispersions
Initially, a hot-melt cast molding method was used to prepare the solid dispersion
systems. PTX, concentrations varied from 10-40%, was homogeneously mixed with PolyOxTM
WSR N-80 and other excipients and heated at the temperature ranged from 140-150°C for 8-10
min. The final formulation was extruded using a ThermoFisher Scientific HAAKE MiniLab II.
The screw speed and processing temperature were set up at 50rpm and 145°C, respectively.
Extrudates were further pelletized and filled into capsules (size 1) for dissolution studies.
5. 1. 3 In vitro dissolution studies
Dissolution studies were performed on a Hanson SR8-Plus™ dissolution test station
(Hanson Research Corporation, Chatsworth, CA) operated at 50 rpm, using four types of
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media, 1) 900 mL pH 6.8 phosphate buffer, 2) 900 mL pH 7.4 phosphate buffer, 3) 900 mL 0.1N
HCl and 4) 750 mL 0.1N hydrochloric acid (pH 1.2) for 2 hours, followed with additional 250
mL 0.2M tribasic sodium phosphate to adjust pH to 7.4 by adding either 2N HCl or NaOH. All
the dissolution studies were conducted for 12 hours. USP apparatus 2 and 5 were utilized for the
dissolution of capsules and patches, respectively. At pre-determined time intervals 1.5mL
samples were removed from the dissolution vessels and replaced with fresh dissolution medium.
These collected samples were immediately filtered using 13mm PTFE membrane filters
(Whatman, Piscataway, NJ) with a pore size of 0.2 µm and analyzed. The release studies were
performed in triplicate and the average values were compared.
5. 1. 4 Differential scanning calorimetry (DSC)
Approximately 5-7 mg samples were weighed and analyzed at 10°C/min heating rate
between 25°C to 250°C using a Perkin-Elmer Diamond DSC instrument (Norwalk, CT)
equipped with Pyris software (Shelton, CT, USA). The instrument was calibrated with indium
and zinc before testing. Nitrogen was used as purge gas at a flow rate of 20 mL/min. All the
experiments were performed in triplicate.
5. 1. 5 Fourier transform infrared spectroscopy (FT-IR)
Fourier transform infrared spectroscopy (FT-IR) studies were conducted on a
PerkinElmer Spectrum 100 FT-IR Spectrometer, equipped with the universal ATR accessory, in
the range of 4000-650 cm-1, using a resolution of 1 cm-1. All the experiments were performed in
triplicate.
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5. 1. 6 Stability
The extrudates were placed in sealed bottles and stored in 25°C/60% RH and 40°C/75%
RH conditions per ICH guidelines. Samples were taken at every month and subjected to DSC
and dissolution studies in the period of storage up to 3 months.
5. 2. 1 Phase Solubility Determination
The aqueous solubility of paclitaxel was determined as 0.7-0.8 µg/ml in different
solutions (Figure 5-1), which is confirmed with the reported value[129]. Also, only slight
difference was observed with the alteration of pH, due to the lack of functional groups which can
be ionized in the structure of paclitaxel. Hence, it is not feasible to improve the solubility of
paclitaxel by common approaches like salts formation[202] and the solubility enhancement of
paclitaxel was challenging to pharmaceutical researchers. Various methods were developed to
promote the solubility of PTX, and the pros and cons of different approaches were thoroughly
discussed in several reviews [129, 135, 136, 203-207].
1
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Figure 5-1: Phase solubility of paclitaxel
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5. 2. 2 Differential Scanning Calorimetry
An endothermic peak of paclitaxel was observe around 223.14°C, followed with a
degradation event, which is consistent with observation from Liggins[208]. No endothermic peak
of PTX was observed in DSC thermograms for the binary physical mixtures of PTX and
PolyOxTM WSR N-80 up to 40% PTX loading (Figure 5-2), which is a supportive sign of the
miscibility/ solubility of PTX in the polymer matrix. Interestingly, no degradation event was
detected in the physical mixtures either, which demonstrated the ability of PolyOx TM WSR N-80
to prevent the thermal degradation of PTX.

Figure 5-2: DSC thermograms of PolyOxTM WSR N-80, paclitaxel, and physical mixtures

86

5. 2. 3 In vitro release study
A. Effect of drug loading
Polyethylene oxide and its low molecular weight analogs (polyethylene glycol) have been
widely employed to improve the aqueous solubility of hydrophobic compounds[209-212], the
reason for the rapid release of poorly water insoluble compounds in the formulation is probably
attributed to its good wettability and solubilizing effect[213]. It has been demonstrated that the
contact angle and the powder surface properties have a significant influence of the dissolution
rate [214, 215]. The possible formation of a polymer film around the drug particles due to the
swelling property of the polymer would modify the surface morphology of the drug associated
with a reduction of contact angle which will further lead to an improved dissolution rate. It is
clearly observed in Figure 5-3 that the solubility of PTX was promoted with an increase in PTX
loading in the solid dispersion matrix when compared to the crystalline PTX; however, the
solubility of PTX in the formulation with 40% loading was only slightly increased and was lower
than the other solid dispersions which illustrated the capacity of PolyOxTM WSR N-80 to
solubilize PTX was approximately 30%. It is worth to pointing out that for all the formulations
demonstrating a solubility enhancement effect, the dissolution medium was clear initially, and
became opaque after 2 hours. This finally resulted in a clear solution again at the end of
dissolution. This process could be correlated to the solubility profile and possibly corresponded
to the precipitation from the supersaturated systems initially, and dissolving into the solution
afterwards. However, this dissolution phenomenon is not in agreement with observations in DSC
thermograms in which 40% PTX was also solubilized in the matrix.
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Figure 5-3: Effect of drug loading on solubility enhancement of paclitaxel

B Effect of different additives
The incorporation of surfactants and other solubilizers into solid dispersions to improve
the solubility of hydrophobic compounds has received considerable attention over the last two
decades [37-40]. The mechanism of solubility enhancement is most probably due to the reduced
interfacial tension between drug and dissolution medium resulting from the increased wettability
of the system. In addition, when the concentration of surfactant is above the critical micelles
concentration (CMC), the solubility of the hydrophobic species will be further enhanced by
incorporation into the surfactant aggregates [41]. Various additives were added into the
formulations and the effect on the solubility enhancement was investigated. With the addition of
sodium lauryl sulfate, an anionic surfactant, the solubility of paclitaxel was higher than the
formulation containing F-68, which is probably due to further reduction in the surface tension of
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SLS[216]. Moreover, PEG 3350 demonstrated a higher solubility enhancement of the PTX,
which is probably due to the good miscibility between PEG 3350 and PolyOxTM WSR N-80.
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Figure 5-4: Effect of different additives on solubility enhancement of paclitaxel
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C. Effect of concentration of PEG 3350
The effect of PEG 3350 concentration on the solubility enhancement of paclitaxel was
further investigated (Figure 5-5). The apparent solubility of paclitaxel was increased with the
increasing of PEG 3350 percentage up to 15%, however, with the addition of 20% PEG 3350,
the solubility of paclitaxel dropped. The solubility enhancement of paclitaxel is most probably
due to PolyOxTM WSR N-80 while the addition of PEG 3350 increased the wettability of
formulations, however, the reduction of solubility of paclitaxel probably indicated the optimal
concentration of PEG 3350 is not beyond 15%.
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Figure 5-5: Effect of concentration of PEG 3350 on solubility enhancement of paclitaxel
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5. 2. 4 Precipitation inhibition with polymers
Supersaturating drug delivery system has been broadly employed to enhance the
solubility of hydrophobic compounds. However, apart from its tremendous advantages on
solubility enhancement, the supersaturating system has the tendency to precipitate when the
formulations are exposed to the dissolution medium, which limits further application. To address
this hurdle, a so-called precipitation inhibitor is usually incorporated into the supersaturating
drug delivery system. Typically, the precipitation of drug from supersaturating drug delivery
system consists of two steps, nucleation and the following crystal growth process. It is important
to point out that the dissolved drug molecules have to overcome an energy barrier, which is due
to the interfacial tension between drug particles and dissolution medium, to form aggregates
(nucleation process), which can further grow to crystals, although the precipitation is
thermodynamically driven by supersaturation. Therefore, the energy barrier itself provides the
possibility to delay or prevent the nucleation process if it could be promoted high enough and the
supersaturation could remain in the metastable state for a longer period of time. Pharmaceutical
excipients like polymers have been widely employed to stabilize the supersaturation systems
based on the mechanism of direct interaction between polymers and drug particles and hydrogen
bonding is the one observed most often. The active energy is increased with the formation of
hydrogen bonds and, furthermore, the polymers will compete with the drug particles to absorb on
the crystals or postpone the absorption by means of steric effects, which will finally lead to a
retarded crystal growth rate[114].
Currently, HPMCAS has been used as a precipitation inhibitor in many studies, and it
demonstrated a superior effect on stabilization of the supersaturating drug delivery system. The
mechanism is mainly attributed to the two properties of HPMCAS itself, 1) it can be partial
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ionized at a pH above 5.5, which results in the stabilization of nano-sized amorphous drugpolymer aggregates; 2) the hydrophobic group in the HPMCAS structure can provide sites for
drug association[178, 217]. It was demonstrated in Figure 5-6 that the apparent solubility of
paclitaxel was maintained up to 12 hours with the addition of 5% HPMCAS-LF, while the
formulation containing 5% HPMCAS-HF showed a lower solubility of PTX, however, the
solubility was also maintained. The difference between AS-LF and AS-HF is succinoyl
substitution to acetyl substitution ratio, which is 15:8 in AS-LF contrasted with a ratio of 6:12 in
AS-HF, leading to that AS-LF can dissolve in solutions of pH 5.5 or higher while AS-HF can
only dissolve in a solution of pH 6.5 or higher. Tanno et al. evaluated the properties of solid
dispersions using HPMCAS as a matrix carrier. AS-HF was observed to provide a slower but
higher and more stable release over the three polymers, however, the dissolution behavior was
different with the alternation of the drug-polymer ratio[218]. Jachowicz et al also reported the
dissolution behavior of piroxicam solid dispersions using HPMCAS as a carrier [219]. The ASHF solid dispersion demonstrated a faster release over AS-LF solid dispersion when the drugpolymer ratio is 1:1, on the other hand, the two solid dispersions revealed similar release profile
when the drug-polymer ratio was adjusted to 1: 5. The reason for the different dissolution
behavior is still not clear and further investigation is necessary; however, it was clear that
substitution of HPMCAS structure had played an important role in the phenomenon. Meanwhile,
other cellulose derivatives and vinyl polymers are also used as stabilizers and the effect of
polymer types was also investigated (Figure 5-7). In the current study, Kollidon® 17PF exhibited
a similar precipitation inhibition effect as AS-LF with a slightly lower maximum solubility and
the precipitation effect of PVP usually depends on different drugs and it most probably affects
the crystal growth rate rather than the nucleation process [220]. Interestingly, beyond the
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precipitation inhibition effect, HPMC E5 also increased the apparent solubility. The reason for
this phenomenon is not yet clear. It seemed that cellulose derivatives have a better precipitation
effect compared to synthetic polymers due to their bulky group in the structure[221]. HPMCASLF was selected into the final formulation, which was further investigated and the evaluation of
HPMC E5 will be continued.
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Figure 5-6: Effect of HPMCAS grade on the precipitation inhibition
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5. 2. 5 Characterization of the final formulation
A. Dissolution in different pH medium
To confirm with phase solubility study conducted previously, the final formulation was
subjected to dissolution study in different pH medium. As shown in Figure 5-8, the formulation
demonstrated the highest solubility in pH 6.8 buffer solution, which is consistent with previous
results. The formulation is subjected to a pH shift method as well which is usually performed as
an alternative method for the investigation of supersaturation behavior of neutral
compounds[222], in order to illustrate the release profile in the whole GI tract. As a result, the
formulation also demonstrated an enhanced solubility and the solubility reduction at 3hrs is due
to the volume change from 750mL to 1000mL, which changed the apparent solubility.
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Figure 5-8: Dissolution of paclitaxel extrudates in different pH medium
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B. Differential Scanning Calorimetry
No characteristic endothermic or degradation peak of paclitaxel was detected in the
extrudates which indicated the existence of amorphous paclitaxel (Figure 5-9). PolyOxTM WSR
N-80 and PEG 3350 exhibited the same spectrum as expected due to the same monomer in their
structures.

Figure 5-9: DSC of paclitaxel, PEG 3350, HPMCAS-LF, PolyOxTM WSR N-80, physical
mixture and extrudates
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C. Fourier transform infrared spectroscopy (FT-IR)
PEO N 80 and PEG 3350 demonstrated the same spectra due to their same monomer. The
stretch peak of the O-H group in pure paclitaxel at 3468.02 cm-1 as well as the stretch peak of the
carbonyl group at 1703 cm-1 were absent in the spectrum of the extrudates (Figure 5-10), which
is probably due to the hydrogen bonding formed between PTX and AS-LF, resulting in the
inhibition of precipitation.

Figure 5-10: FT-IR of paclitaxel, PEG 3350, HPMCAS-LF, PolyOxTM WSR N-80, physical
mixture and extrudates
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D. Stability
Stability is of paramount importance for formulation development, and therefore, the
solid dispersion formulation was subjected to two storage conditions for three months, 25°C/60%
RH and 40°C/75% RH per ICH guidelines. No crystallization evidence was detected in DSC
thermograms indicating excellent physical stability (Figure 5-11), in addition the chemical
stability was confirmed with the similar dissolution profile when compared to the fresh
extrudates.

Figure 5-11: DSC of paclitaxel, fresh extrudates, and stability samples stored at 25°C/60% RH
and 40°C/75% RH (at 3 month)
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CHAPTER 6
SUMMARY AND CONCLUSIONS
6.1 Summary
Over the last few decades, hot-melt extrusion (HME) has been well adapted into the
pharmaceutical industry to enhance the solubility and bioavailability of poorly water soluble
compounds by producing amorphous solid dispersions. It is critical to understand the
miscibility/solubility of active pharmaceutical ingredient (API) within the polymeric carriers to
determine the suitable drug load range. Additionally, processing parameters also play an
important role in the formulation development utilizing HME.
In chapter 2, a melting point depression approach was applied to determine the
miscibility/solubility of two poorly water soluble compounds felodipine and ketoconazole within
an amphiphilic polymer Soluplus®. The plot of free energy of mixing vs concentration indicates
felodipine is more miscible with Soluplus® than ketoconazole. Further, the Flory-Huggins phase
diagrams of both systems confirmed the assumption with a predicted solubility 14% (w/w) of
felodipine within Soluplus® compared to 4.3% (w/w) of ketoconazole at room temperature
(298K).
In chapter 3, the utility of Soluplus® as a polymeric carrier for solubility enhancement of
felodipine was investigated. Beyond the use of the melting point depression method, solubility
parameters and heat of fusion were also employed in the present study to determine the
miscibility of felodipine within Soluplus®. With the incorporation of pre-dissolved Soluplus®,
the solubility of felodipine was further elevated which indicated the possible utility of Soluplus®
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as a surfactant. Both of FT-IR and Raman spectroscopy studies demonstrated the formation of
intermolecular interaction between felodipine and Soluplus®. In addition, morphology study
indicated that felodipine could be molecularly dispersed within Soluplus® at a concentration of
10%.
In chapter 4, a center composite design (CCD) was applied to investigate the influence of
formulation factors and processing parameters on the ketoconazole-Soluplus® melt extrudates.
Finally, an optimized formulation containing 29.8% ketoconazole was extruded at 140°C/31rpm.
The final formulation released 72.80±1.31% at 15min with an average post extrusion content of
97.68±4.38%. Furthermore, DSC and morphology studies indicated the amorphous state of
ketoconazole. Collectively, these data suggested that considerable attention needs to be paid to
both the formulation and processing factors developing hot melt extruded dosage forms.
In chapter 5, a novel formulation containing 30% paclitaxel, 15% PEG3350, 5%
HPMCAS-LF and 50% PolyOxTM WSR N-80 was prepared utilizing hot-melt extrusion
technology. The formulation maintained a minimum solubility of paclitaxel as 7.66µg/mL for 12
hours. Due to the absence of Cremophor® EL, the formulation is expected to avoid severe side
effects. Moreover, the present study demonstrated the possible utility of hot-melt extrusion
technology as an alternative approach for formulation development of high melting point
compounds.
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6.2 Future Prospective
 Employ melting point depression method to model more compounds and to understand
the relationship between the physical properties of the model compounds and miscibility
with Soluplus®
 Employ design of experiments to larger size twin screw extruder and investigate the
scalability of the final formulation of ketoconazole
 Investigate the reason for the further solubility enhancement of paclitaxel with addition
of HPMC E5
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